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A B S T R A C T
Background
Linezolid was recently re-classified as a Group A drug by theWorld Health Organization (WHO) for treatment of multi-drug resistant
tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), suggesting that it should be included in the regimen
for all patients unless contraindicated. Linezolid use carries a considerable risk of toxicity, with the optimal dose and duration remaining
unclear. Current guidelines are mainly based on evidence from observational non-comparative studies.
Objectives
To assess the efficacy of linezolid when used as part of a second-line regimen for treating people with MDR and XDR pulmonary
tuberculosis, and to assess the prevalence and severity of adverse events associated with linezolid use in this patient group.
Search methods
We searched the following databases: the Cochrane Infectious Diseases Specialized Register; CENTRAL; MEDLINE; Embase; and
LILACS up to 13 July 2018. We also checked article reference lists and contacted researchers in the field.
Selection criteria
We included studies in which some participants received linezolid, and others did not. We included randomized controlled trials (RCTs)
of linezolid for MDR and XDR pulmonary tuberculosis to evaluate efficacy outcomes. We added non-randomized cohort studies to
evaluate adverse events.
Primary outcomes were all-cause and tuberculosis-associated death, treatment failure, and cure. Secondary outcomes were treatment
interrupted, treatment completed, and time to sputum culture conversion. We recorded frequency of all and serious adverse events,
adverse events leading to drug discontinuation or dose reduction, and adverse events attributed to linezolid, particularly neuropathy,
anaemia, and thrombocytopenia.
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Data collection and analysis
Two review authors (BS and DC) independently assessed the search results for eligibility and extracted data from included studies.
All review authors assessed risk of bias using the Cochrane ‘Risk of bias’ tool for RCTs and the ROBINS-I tool for non-randomized
studies. We contacted study authors for clarification and additional data when necessary.
We were unable to perform a meta-analysis as one of the RCTs adopted a study design where participants in the study group received
linezolid immediately and participants in the control group received linezolid after two months, and therefore there were no comparable
data from this trial. We deemed meta-analysis of non-randomized study data inappropriate.
Main results
We identified three RCTs for inclusion. One of these studies had serious problems with allocation of the study drug and placebo, so
we could not analyse data for intervention effect from it. The remaining two RCTs recruited 104 participants. One randomized 65
participants to receive linezolid or not, in addition to a background regimen; the other randomized 39 participants to addition of
linezolid to a background regimen immediately, or after a delay of two months. We included 14 non-randomized cohort studies (two
prospective, 12 retrospective), with a total of 1678 participants.
Settings varied in terms of income and tuberculosis burden. One RCT and 7 out of 14 non-randomized studies commenced recruitment
in or after 2009. All RCT participants and 38.7% of non-randomized participants were reported to have XDR-TB.
Dosing and duration of linezolid in studies were variable and reported inconsistently. Daily doses ranged from 300 mg to 1200 mg;
some studies had planned dose reduction for all participants after a set time, others had incompletely reported dose reductions for some
participants, and most did not report numbers of participants receiving each dose. Mean or median duration of linezolid therapy was
longer than 90 days in eight of the 14 non-randomized cohorts that reported this information.
Duration of participant follow-up varied between RCTs. Only five out of 14 non-randomized studies reported follow-up duration.
Both RCTs were at low risk of reporting bias and unclear risk of selection bias. One RCT was at high risk of performance and detection
bias, and low risk for attrition bias, for all outcomes. The other RCT was at low risk of detection and attrition bias for the primary
outcome, with unclear risk of detection and attrition bias for non-primary outcomes, and unclear risk of performance bias for all
outcomes. Overall risk of bias for the non-randomized studies was critical for three studies, and serious for the remaining 11.
One RCT reported higher cure (risk ratio (RR) 2.36, 95% confidence interval (CI) 1.13 to 4.90, very low-certainty evidence), lower
failure (RR 0.26, 95% CI 0.10 to 0.70, very low-certainty evidence), and higher sputum culture conversion at 24 months (RR 2.10,
95% CI 1.30 to 3.40, very low-certainty evidence), amongst the linezolid-treated group than controls, with no differences in other
primary and secondary outcomes. This study also found more anaemia (17/33 versus 2/32), nausea and vomiting, and neuropathy
(14/33 versus 1/32) events amongst linezolid-receiving participants. Linezolid was discontinued early and permanently in two of 33
(6.1%) participants who received it.
The other RCT reported higher sputum culture conversion four months after randomization (RR 2.26, 95% CI 1.19 to 4.28), amongst
the group who received linezolid immediately compared to the group who had linezolid initiation delayed by two months. Linezolid
was discontinued early and permanently in seven of 39 (17.9%) participants who received it.
Linezolid discontinuation occurred in 22.6% (141/624; 11 studies), of participants in the non-randomized studies. Total, serious, and
linezolid-attributed adverse events could not be summarized quantitatively or comparatively, due to incompleteness of data on duration
of follow-up and numbers of participants experiencing events.
Authors’ conclusions
We found some evidence of efficacy of linezolid for drug-resistant pulmonary tuberculosis from RCTs in participants with XDR-TB
but adverse events and discontinuation of linezolid were common. Overall, there is a lack of comparative data on efficacy and safety.
Serious risk of bias and heterogeneity in conducting and reporting non-randomized studies makes the existing, mostly retrospective,
data difficult to interpret. Further prospective cohort studies or RCTs in high tuberculosis burden low-income and lower-middle-
income countries would be useful to inform policymakers and clinicians of the efficacy and safety of linezolid as a component of drug-
resistant TB treatment regimens.
P L A I N L A N G U A G E S U M M A R Y
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Linezolid for managing people with drug-resistant tuberculosis
What is drug-resistant tuberculosis, and how might linezolid work?
Tuberculosis is caused by infection with Mycobacterium tuberculosis bacteria. When there are symptoms or signs of illness, this is called
active tuberculosis. An estimated one-third of the world’s population are infected with tuberculosis, and around 1.4 million people
died from active tuberculosis in 2015.
Bacteria that cause tuberculosis can develop resistance to the drugs most commonly used to treat tuberculosis, also called first-line
antibiotics. This is an increasing problem that makes treatment more difficult, because second-line tuberculosis treatment drugs are
less powerful against the bacteria, and more likely to cause harmful effects. Standard treatment for drug-resistant tuberculosis requires
patients to take multiple antibiotics for nearly two years. Linezolid is a second-line drug that laboratory studies have found to be good
at killing bacteria that cause tuberculosis, but that can also cause frequent, serious harmful effects.
The review question
Recent international guidelines recommend trying to include linezolid in the treatment of all patients with multi-drug resistant
tuberculosis, but there is concern about whether enough good evidence exists to tell us how well it works, what dose is best, and how
safe it is for people who take it.
Study characteristics
We searched for evidence up to 13 July 2018. We analysed data from two trials, one of which randomly allocated 65 people with
drug-resistant tuberculosis to either a linezolid-containing or linezolid-free drug combination, and another that randomly allocated 39
participants to receive linezolid as part of their treatment from the start or have it added after a delay of two months. We also included
14 studies, including 1678 people, in which some participants received linezolid but others did not, but this was not determined at
random.
What are the main results of the review?
One trial showed a higher likelihood of cure and lower risk of treatment failure in participants receiving linezolid compared to those
who did not. The second trial showed that participants who received linezolid immediately had a higher chance of tuberculosis being
cleared from their sputum four months after the start of the study than those who added linezolid after a two-month delay.
When they examined safety, the first trial found a higher risk of developing low red blood cell counts, nausea and vomiting, and nerve
damage in people receiving linezolid. From 11 of the non-randomized studies that reported this, 22.6% of people had to stop linezolid
due to adverse effects (side effects), though further comparisons of harmful effects were not possible due to incomplete reporting in the
non-randomized studies.
Overall, although there is some evidence of benefit, we have very low certainty in its accuracy. More high-quality studies are required
before we can be certain how effective and safe linezolid is for drug-resistant tuberculosis.
How up-to-date is this review?
This review is current up to 13 July 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Linezolid compared to no linezolid for drug- resistant pulmonary tuberculosis
Patient or population: drug-resistant pulmonary tuberculosis
Setting: one study (Tang 2015): China; all adults; all extensively drug resistant; no part icipants with HIV (excluded)
Intervention: l inezolid
Comparison: no linezolid
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence (GRADE)
Comments
Risk with no linezolid Risk with linezolid
Death 9 per 100 6 per 100
(1 to 34)
RR 0.65
(0.12 to 3.62)
65
(1 RCT)
⊕©©©
Very lowa,b,c,d
due to risk of bias, im-
precision, and indirect-
ness
We are uncertain
whether or not linezolid
reduces death
Treatment failure 47 per 100 12 per 100
(5 to 33)
RR 0.26
(0.10 to 0.70)
65
(1 RCT)
⊕©©©
Very lowa,b,d,e
due to risk of bias, im-
precision, and indirect-
ness
We are uncertain
whether or not linezolid
reduces treatment fail-
ure
Cure 22 per 100 52 per 100
(25 to 100)
RR 2.36
(1.13 to 4.90)
65
(1 RCT)
⊕©©©
Very lowa,b,d,f
due to risk of bias, im-
precision, and indirect-
ness
We are uncertain
whether or not linezolid
increases cure
Treatment interrupted 9 per 100 12 per 100
(3 to 50)
RR 1.29
(0.31 to 5.33)
65
(1 RCT)
⊕©©©
Very lowa,b,c,d
due to risk of bias, im-
precision, and indirect-
ness
We are uncer-
tain whether or not line-
zolid reduces treatment
interrupt ion
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Treatment completed 13 per 100 18 per 100
(6 to 59)
RR 1.45
(0.45 to 4.68)
65
(1 RCT)
⊕©©©
Very lowa,b,c,d
due to risk of bias, im-
precision, and indirect-
ness
We are
uncertain whether line-
zolid increases treat-
ment complet ion as the
certainty of the evi-
dence is very low
Sputum culture con-
version
at 24 months
38 per 100 79 per 100
(49 to 100)
RR 2.1
(1.3 to 3.4)
65
(1 RCT)
⊕©©©
Very lowb,d,f
due to risk of bias, im-
precision, and indirect-
ness
We are uncer-
tain whether or not line-
zolid increases sputum
culture conversion
Total adverse eventsg 28 (32 part icipants) in no-linezolid group; 74 (33
part icipants) in linezolid groupg
- 65
(1 RCT)
⊕©©©
Very lowa,d,h,i
due to risk of bias, im-
precision, and indirect-
ness
We are uncer-
tain whether or not line-
zolid reduces total ad-
verse events
Serious adverse events - - - - - Not reported
Antituberculous treat-
ment
discontinuationj
3 per 100 6 per 100
(1 to 64)
RR 1.94
(0.18 to 20.35)
65
(1 RCT)
⊕©©©
Very lowa,b,d,k
due to risk of bias, im-
precision, and indirect-
ness
We are un-
certain whether or not
linezolid reduces ant i-
tuberculous treatment
discont inuat ion
Linezolid discontinua-
tionl
2/ 33 part icipants receiving linezolid had perma-
nent discont inuat ion of linezolid
- 65
(1 RCT)
- Comparison is not pos-
sible for this outcome
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
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Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aNo serious inconsistency: only one study was included.
bDowngraded by one level for serious indirectness: the populat ion (drug-resistant tuberculosis), though meeting criteria for
inclusion in the review, only included adults, who had extensively drug-resistant tuberculosis, and tested negat ive for HIV
infect ion. Recruitment was f rom only one country (China). Part icipants were excluded if they could not af ford linezolid.
cDowngraded by two levels for very serious imprecision: the CI is wide, and the event rate is low.
dDowngraded by two levels for risk of bias: random sequence generat ion and allocat ion concealment were not described,
therefore leading to unclear risk of bias. There was no blinding, nor placebo control, so there was a high risk of performance
and detect ion bias.
eSerious imprecision, due to small sample size.
fDowngraded by two levels for very serious imprecision: the CI is wide and sample size is small.
gDue to lack of report ing of follow-up durat ion, we were unable to calculate a risk rat io.
hDowngraded by one level for serious indirectness: due to lack of follow-up durat ion data, we were unable to perform
comparat ive analysis for this outcome.
iDowngraded by two levels for very serious imprecision, due to inability to calculate risk rat io.
jAntituberculous treatment (ATT): a further two part icipants in each group discont inued ATT due to inability to af ford the
drugs. We included only discont inuat ions due to clinical reasons in the results, for the purpose of the review.
kDowngraded by two levels for very serious imprecision: number of events was small, with a result ing wide CI, ranging f rom
very large increase to an 82% decrease in discont inuat ion.
lSome part icipants discont inued linezolid temporarily, but the number of those was not reported. Part icipants discont inuing
linezolid due to being unable to af ford it (n = 2) are not included in this number.
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B A C K G R O U N D
Description of the condition
Tuberculosis is caused by infection with bacteria of the Mycobac-
terium tuberculosis complex. It remains one of the leading infec-
tious causes of death worldwide; there were 1.4 million deaths
from tuberculosis worldwide in 2015, with an additional 0.4 mil-
lion deaths from tuberculosis amongst people living with HIV
(WHO2016b). Pulmonary tuberculosis is themost common form
of tuberculosis, and the most important from a public health per-
spective because tuberculosis is transmitted by aerosolized droplets
from people with active pulmonary tuberculosis when they cough
(Vashishtha 2013). It is estimated that around one third of the
world’s population are infectedwith tuberculosis, although of these
only one in ten will develop active tuberculosis disease (WHO
2009).
Most people with tuberculosis are infected with strains ofM tuber-
culosis that are treatable with the standard first-line drugs recom-
mended by theWorldHealthOrganization (WHO) guidelines: ri-
fampicin, isoniazid, pyrazinamide, and ethambutol (WHO 2010).
Early diagnosis and treatment with effective drugs is a mainstay
of tuberculosis disease control, as well as being a life-saving inter-
vention for people with tuberculosis.
Multidrug-resistant tuberculosis (MDR-TB) is tuberculosis dis-
ease that is caused byMtuberculosis strains that have acquired resis-
tance to two important drugs in the first-line regimen: rifampicin
and isoniazid (Sharma 2006). Rifampicin-monoresistant tubercu-
losis is often managed as MDR-TB (WHO 2016a). Extensively
drug-resistant tuberculosis (XDR-TB), occurs when M tubercu-
losis strains are resistant to rifampicin, isoniazid, and any of the
antibiotics in the fluoroquinolone class, as well as any of the three
injectable drugs used in the second-line treatment of tuberculosis:
amikacin, kanamycin, and capreomycin (WHO 2016a).
The WHO estimates that 480,000 cases of MDR-TB occurred in
2015, with 190,000 deaths worldwide, and an estimated 9.5% of
people with MDR-TB actually having XDR-TB (WHO 2016b).
Detection of drug-resistant tuberculosis is challenging and cur-
rently requires costly laboratory services. Access to effective treat-
ment is far from universal. Despite rapid progress, only 12% of
new tuberculosis cases were tested for drug resistance in 2014,
with case detection at only 41% (WHO 2015a). Over the last
decade treatment success rates have remained static at around 50%
(WHO2015a), and the international tuberculosis community has
recognized that newdrugs and regimenswith improved efficacy are
urgently needed to improve cure rates. The WHO End TB Strat-
egy outlines measures for post-2015 tuberculosis control; these
include a goal to detect and treat everyone with drug-resistant tu-
berculosis, which will require significant scaling up of resources
and efforts (WHO 2014).
Constructing drug-resistant tuberculosis chemotherapy regimens
is difficult; several of the available agents are expensive and toxic,
and efficacy is uncertain because data from clinical studies are lim-
ited (Chang 2013a). This is especially true for XDR-TB. Treat-
ment for drug-resistant tuberculosis is long: conventional regi-
mens are administered for a total of 20 months for most patients,
with an initial intensive phase of around eight months, dependent
upon response to therapy (WHO 2016a). This has led to efforts
being channeled towards investigation of new and existing drugs
and regimens, with a drive to shorten treatment duration, stan-
dardize study design and reporting (Mitnick 2015), and focus on
low-resource settings that are disproportionately affected by tu-
berculosis and MDR-TB globally (Sloan 2016).
Description of the intervention
Linezolid was categorized as a ‘Group 5’ drug in the 2011 WHO
drug-resistant tuberculosis guidelines (WHO 2011). Medications
assigned to this groupwere not recommended for use as core drugs,
due to insufficient evidence detailing their safety or efficacy. How-
ever, the 2016 WHO update re-allocated it as a ‘Group C: other
core second-line agent’, prioritizing its use over some more tra-
ditional agents (WHO 2016a). The number of linezolid-treated
patients included in reviews of evidence informing both the 2011
and 2016 WHO guidance was insufficient to provide efficacy and
safety estimates (WHO 2011, Fox 2017). In 2018, in a rapid
communication from the WHO on treatment of MDR-TB and
rifampicin-monoresistant-TB, linezolid’s position was further up-
graded to a ‘group A: Medicines to be prioritised’ (WHO 2018).
A summary of evidence for the 2018 recommendation has been
published (Ahmad 2018).
Despite the promoted status of linezolid, concerns about serious
adverse effects prompted the 2016 WHO update to caution that
where closemonitoring for adverse events is unavailable, “linezolid
would best be reserved forMDR-TB patients who have additional
drug resistance...or who are intolerant to other components of the
core regimen” (WHO 2016a). The 2018 WHO rapid communi-
cation, which recommends linezolid for all people with MDR-TB
unless it cannot be used, still states that, “Optimal duration of use
of Lzd [linezolid] is not established. Use for at least 6 months was
shown to be highly effective, although toxicity may limit its use”
(WHO 2018).
Five meta-analyses have examined the evidence for linezolid
in drug-resistant tuberculosis (Cox 2012; Sotgiu 2012; Chang
2013c; Zhang 2015; Ahmad 2018). They include mostly obser-
vational data, much of it retrospective. Few randomized studies
have been undertaken. There remains much debate surrounding
linezolid, due to the lack of high-quality evidence. Many suggest
it should be more widely used, hence its upgrade in the recent
WHO guidance (Caminero 2015; Ahmad 2018; WHO 2018).
Considerable reliance on retrospective data may have exacerbated
the effect of confounders in themeta-analyses of treatment efficacy
(Cox 2012; Sotgiu 2012; Chang 2013c; Zhang 2015; Ahmad
2018). These reviews also selected, and focus on, efficacy rather
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than safety. As highlighted by the WHO documents, safety is a
major area of concern with linezolid (Ramachandran 2015).
How the intervention might work
Linezolid is an oxazolidinone antibiotic that disrupts protein syn-
thesis by binding to the 70S initiation complex of bacterial ribo-
somes (Sloan 2016). It also binds to human mitochondria and
inhibits protein synthesis, which is the mechanism of toxicity in
clinical use (De Vriese 2006). It is active against most Gram-posi-
tive bacteria, with extensive evidence of in vitro activity against iso-
lates of M tuberculosis, including those resistant to first-line drugs
(Erturan 2005; Huang 2008).
Linezolid can be taken orally or intravenously. Its excellent oral
bioavailability is an advantage, avoiding the need for long-term
daily injections (Dryden 2011). Though an adult dose of 600 mg
twice daily is commonly used for up to 28 days to treat infec-
tions due to Gram-positive bacteria, a variety of dosing strategies
have been used in the context of drug-resistant tuberculosis, where
treatment duration is much longer. These have ranged from 300
mg to 1200 mg daily, with once- or twice-daily administration.
Lower doses have been tried in an attempt to increase tolerability
and reduce toxicity (Park 2006; Migliori 2009; Yew 2009; Koh
2012). A thrice-weekly intermittent dosing regimen has also been
attempted in limited cohorts to extend the duration of linezolid
therapy (Chang 2013b). The optimal dosing and duration of line-
zolid remains unclear from the perspective of preventing emer-
gence of resistance, as well as efficacy, tolerability, and toxicity.
Adverse effects of linezolid include suppressionof the bonemarrow
causing anaemia and thrombocytopenia, peripheral neuropathy,
and optic neuropathy leading to disability and blindness, which is
usually irreversible. More commonly, gastrointestinal upset may
lead to difficulties with adherence (Ramachandran 2015). Adverse
events with courses of linezolid longer than one month appear to
be common within antituberculous drug regimens, affecting over
80% of participants in some studies (Lee 2012).
Why it is important to do this review
We set out to perform a systematic review reporting on the efficacy
of linezolid for drug-resistant tuberculosis, balanced against an
estimate of the risk of linezolid-associated adverse events. Such
estimates will assist policy makers who are deciding on the place of
linezolid in their national and regional drug-resistant tuberculosis
programmes, as well as individual clinicians trying to interpret the
wide variety of published data on how effective, safe, and tolerable
linezolid is in people being treated for MDR-TB and XDR-TB.
Existing evidence, while of low quality, has concluded that line-
zolid is efficacious in MDR-TB, leading to its inclusion as a drug
to be prioritized in the latestWHOguidance (WHO 2018).How-
ever, evidence regarding appropriate dosing and duration is lack-
ing. Importantly, as linezolid is rolled out for wider use, closer
interrogation of the adverse events data is desirable.
O B J E C T I V E S
To assess the efficacy of linezolid when used as part of a second-
line regimen for treating people with MDR and XDR pulmonary
tuberculosis, and to assess the prevalence and severity of adverse
events associated with linezolid use in this patient group.
M E T H O D S
Criteria for considering studies for this review
Types of studies
To assess the efficacy of linezolid we included randomized con-
trolled trials (RCTs) and quasi-RCTs.
To assess the prevalence and severity of adverse events associated
with the use of linezolid, we included RCTs and quasi-RCTs, and
both prospective and retrospective, non-randomized cohort stud-
ies, as defined by the Cochrane Handbook for Systematic Reviews
of Interventions (Loke 2011), in which some participants received
linezolid and others did not.
Types of participants
Adults and children with a diagnosis of MDR (including ri-
fampicin-monoresistant, managed as MDR) or XDR pulmonary
tuberculosis.
Types of interventions
Intervention
Antituberculous treatment (ATT) regimens that contained line-
zolid at any dose and for any duration.
Control
ATT regimens that did not contain linezolid.
Types of outcome measures
These outcomemeasures are based on those specified by theWHO
for tuberculosis programme outcome reporting in MDR- and
XDR-TB (WHO 2013).
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Primary outcomes
• All-cause death: all deaths that occurred during each
included study and until the end of follow-up
• Tuberculosis-associated death: all deaths attributed to
tuberculosis by the study investigators that occurred during each
study and until the end of follow-up
• Treatment failure: participants who did not show
conversion from sputum culture positive to negative by the end
of the intensive phase of ATT, or who had reverted from culture-
negative to culture-positive, or who had failed to respond
clinically to treatment as defined by the study investigators
• Cure: participants who completed ATT as planned without
evidence of failure and had at least three consecutive negative
sputum cultures in specimens taken at least 30 days apart after
the intensive phase of treatment.
Secondary outcomes
• Treatment interrupted: participants who stopped taking
ATT for one month or longer at any point in the course of
treatment
• Treatment completed: participants who completed ATT as
planned but did not have at least three consecutive negative
sputum cultures in specimens taken at least 30 days apart after
the intensive phase of treatment
• Time to sputum culture conversion: the length of time
between starting treatment and conversion from sputum culture
positive to sputum culture negative.
Adverse events
• All adverse events
• All serious adverse events
• Adverse events that led to discontinuation of
antituberculous drugs or dose reduction
• Adverse events attributed to linezolid, particularly
peripheral and optic neuropathy, anaemia, thrombocytopenia,
lactic acidosis, and serotonin syndrome
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases for relevant studies using the
search terms detailed in Appendix 1:
• the Cochrane Infectious Diseases Specialized Register
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2018, Issue 7) published in the Cochrane Library
• MEDLINE (PubMed)
• Embase (OVID)
• LILACS
We also checked the WHO International Clinical Trials Registry
Platform (WHO ICTRP; www.who.int/ictrp/en/), and Clinical-
Trials.gov (clinicaltrials.gov/ct2/home), for ongoing studies using
the terms: ‘linezolid’ and ‘tuberculosis’.
The latest searches were conducted on 13 July 2018.
Searching other resources
We contacted researchers in the field to identify unpublished or
ongoing studies.
Data collection and analysis
Selection of studies
Two review authors (BS and DC) screened the titles and abstracts
of the search results independently and coded them as either ‘re-
trieve’ (eligible or potentially eligible/unclear), or ‘do not retrieve’.
We retrieved the full-text study reports of all potentially eligi-
ble studies and two review authors (BS and DC) independently
screened them for inclusion and recorded the reasons for exclusion
of ineligible studies. We resolved any disagreement through dis-
cussion or, when required, we consulted a third review author. We
identified and excluded duplicates and collated multiple reports
of the same study so that each study, rather than each report, was
the unit of interest in the review. We contacted study authors for
clarification if a study’s eligibility was unclear.We resolved any dis-
agreements through discussion and listed the excluded studies and
the reasons for their exclusion in the Characteristics of excluded
studies table. We recorded the selection process in sufficient detail
to complete a PRISMA flow diagram (Moher 2009; Figure 1).
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Figure 1. Study flow diagram
Data extraction and management
We designed and piloted a data extraction form, and modified the
form based on the results of the pilot. Two review authors (BS
and DC) independently extracted data from each included study
using the finalized data extraction form. BS and DC compared
the extracted data to identify any possible errors, and resolved any
discrepancies through discussion and by referring to the original
study articles. We extracted the following data from each included
study, where available.
• Country and clinical setting, start and end dates of the
study, study design, inclusion and exclusion criteria, number of
participants eligible for inclusion and number of participants
allocated to each group
• Participant characteristics: age, sex, history of previous
tuberculosis treatment, known contact with MDR-TB patient,
duration of symptoms at presentation, comorbidity (HIV
infection, other immunosuppression and other diseases),
diagnostic methods used (e.g. culture-based drug susceptibility
testing, Xpert MTB/RIF, line probe assay for drug susceptibility),
drug susceptibility profile of participants at entry to the study
• Intervention data: description of drugs, dose, route of
administration in both the intensive and continuation phase,
and duration of all drugs for both phases. Administration of
other drugs or therapeutic procedures, including surgery
Primary outcomes
For the primary outcomes we extracted the following data.
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All-cause death
• Number of deaths, stratified by drug susceptibility profile,
age and HIV status
• Timing of death after start of treatment
Tuberculosis-associated death
• Number of deaths attributed to tuberculosis by the
investigators, stratified by drug susceptibility profile, age and
HIV status
Treatment failure
• Number of participants who did not show sputum culture
conversion by the end of the intensive phase of ATT, stratified by
drug susceptibility profile, age and HIV status
• Number of participants who reverted from culture negative
to culture positive, stratified by drug susceptibility profile, age
and HIV status
• Number of participants who failed to respond clinically to
treatment as defined by the investigators, stratified by drug
susceptibility profile, age and HIV status
• Method of monitoring treatment and defining treatment
failure
• Time between start of treatment and treatment failure
• Outcome following classification as treatment failure
Cure
• Number of participants who completed ATT as planned
and had at least three negative sputum cultures in specimens
taken at least 30 days apart during the last months of treatment,
stratified by drug susceptibility profile, age, and HIV status
Secondary outcomes
For the secondary outcomes we extracted the following data.
Treatment interrupted
• Number of participants who stopped taking ATT for one
month or more at any point in the course of treatment, stratified
by drug susceptibility profile, age and HIV status
• Method of monitoring treatment adherence
• Reasons for treatment interruption
Treatment completed
• Number of participants who completed ATT as planned
but did not have at least three negative sputum cultures in
specimens taken at least 30 days apart during the last months of
treatment.
• Method of monitoring treatment.
Time to sputum culture conversion
• Time between starting treatment and conversion from
sputum culture positive to sputum culture negative
• Method of monitoring treatment, including frequency of
sputum sampling
Follow-up
Length of follow-up, follow-up methods, number and character-
istics of losses to follow-up.
Adverse events
We extracted information on the total number of the following.
• Adverse events
• Serious adverse events
• Participants experiencing adverse events
• Adverse events that led to discontinuation of
antituberculous drugs or linezolid dose reduction
• Adverse events attributed to linezolid, particularly
peripheral and optic neuropathy, anaemia, thrombocytopenia,
lactic acidosis, and serotonin syndrome
For each outcome, we extracted the number of participants as-
signed and the number of participants analysed in each treatment
group. For dichotomous outcomes, we extracted the number of
participants who experienced the event. For count data outcomes,
we extracted the number of events in the intervention and control
groups.
Assessment of risk of bias in included studies
For RCTs and quasi-RCTs, two review authors independently as-
sessed the methodological quality of each included study using
the Cochrane ‘Risk of bias’ tool and reported the results in a ‘Risk
of bias’ table (Higgins 2011a). We resolved any disagreements
through discussion. Regarding generation of allocation sequence
and allocation concealment, we classified each as either adequate,
inadequate, or unclear in each included study according to Jüni
2001. We reported who was blinded in each included study, and
we assessed the risk of bias associated with blinding separately for
each primary outcome. If at least 90% of participants were fol-
lowed up to study completion we classified inclusion of all ran-
domized participants as adequate; otherwise we classified inclu-
sion as inadequate. We attempted to contact the study authors if
information was unspecified or unclear.
For non-randomized studies, we used the ROBINS-I risk of bias
tool (Sterne 2016), and adapted and piloted it before we used it
to assess all included non-randomized studies. The following are
areas of confounding that we expected to be relevant to all or most
included studies.
• Extent of drug resistance: number of effective drugs
available
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• Severity of tuberculosis disease at start of treatment
• HIV co-infection
• Timing of addition of linezolid to the regimen
• Duration of linezolid treatment
• Background antituberculous therapy regimen (the other
drugs composing the overall regimen)
• Supportive care available in study setting
Measures of treatment effect
We used risk ratio (RR) as the measure of treatment effect for
analysis.
Unit of analysis issues
We did not anticipate that any cluster-RCTs would meet the in-
clusion criteria of the review.
For multi-armed studies, where we wished to include more than
one intervention study arm, we planned to split the control group
to avoid including the same participants more than once.
Dealing with missing data
The primary analysis was an intention-to-treat analysis where all
participants randomized to treatment were included in the de-
nominator. This analysis assumed that all people lost to follow-up
did not have the outcome in question. We carried out a sensitivity
analysis to explore the impact of missing data on the summary
effect estimates for all-cause death, cure and failure.
Assessment of heterogeneity
We planned to assess heterogeneity by visually inspecting the for-
est plots to determine closeness of point estimates to each other
and overlap of confidence intervals (CIs). We planned to use the
Chi² test with a P value of 0.10 to indicate statistical significance
(Deeks 2017), and the I² statistic (Higgins 2003), to assess hetero-
geneity with a value of 50% taken to indicate significant statistical
heterogeneity.
Assessment of reporting biases
We planned to conduct visual inspection of the funnel plot of
the studies for any obvious asymmetry that could be evidence of
publication bias if we included at least 10 studies.
Data synthesis
Using Review Manager 5 (RevMan 5), we planned to perform a
meta-analysis on the data in included studies, but not to combine
data from RCTs and non-randomized studies (Review Manager
2014). As we anticipated significant variability in samples from
participants across the different studies, we planned to use a ran-
dom-effects model for meta-analysis, unless there was a very small
number of included studies with low heterogeneity, in which case
we planned to use a fixed-effect model.
For non-randomized data, we did not plan to perform a meta-
analysis. We planned to report these data descriptively in a table
that included how the data were collected, and the reported out-
comes (unadjusted). If the study authors had adjusted data, we
planned to provide this estimate with a short description of the
adjustments the study authors made.
We assessed the certainty of the evidence using the GRADE ap-
proach. We used GRADEpro GDT software to construct a ‘Sum-
mary of findings’ table (GRADEpro GDT 2015).
Subgroup analysis and investigation of heterogeneity
We planned to investigate heterogeneity through the following
subgroup analyses.
• Drug-resistance profile, determined by:
◦ % XDR
◦ % fluoroquinolone-resistant (resistant to any
fluoroquinolone, but susceptible to injectables)
◦ % injectable-resistant (resistant to any injectable, but
susceptible to fluoroquinolones)
• HIV status (seropositive and seronegative)
• Age (adults and children)
• Daily dose of linezolid (600 mg or less and over 600 mg
adult equivalent)
• Duration of linezolid (six months or less and longer than six
months)
• Total cumulative dose of linezolid
• Other drugs within the background antituberculous drug
regimen
Sensitivity analysis
Weperformed a worst-case scenario analysis by imputing themiss-
ing data as poor outcomes in the linezolid group and good out-
comes in the control group, and by comparing this to an available-
case analysis to explore the effect of missing data on the primary
outcomes all-cause death, cure and failure.
R E S U L T S
Description of studies
Results of the search
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Searches identified 781 records. Of these, we excluded 23 dupli-
cate records. Of the remaining 758, we excluded 621 after assess-
ing titles and abstracts. Following this, we retrieved 137 full-text
publications to assess for inclusion. Figure 1 shows the screening
process in a flow diagram.
Included studies
We included 17 studies: three randomized studies (138 partic-
ipants), and 14 non-randomized cohort studies (1678 partici-
pants), of which two were prospective and 12 were retrospective
(Figure 1). A summary description is provided in Table 1, with
more detailed characteristics in the ‘Characteristics of included
studies’ section.
Geographical location and time period
The RCTs were conducted in the Republic of Korea, South Africa
and China.
Locations were diverse amongst the non-randomized studies.
Three were based in the Republic of Korea; a low tuberculosis
burden and low MDR-TB burden country (Jo 2014; Jeong 2015;
Kwak 2015), according to WHO definitions of tuberculosis, tu-
berculosis/HIV andMDR-TB burden (WHO 2015b). Four were
conducted in low tuberculosis burden and low MDR-TB burden
European countries; Netherlands (Van Altena 2015), Italy (Galli
2016), Norway (Jensenius 2016) and France (Guglielmetti 2017).
Two studies recruited from Europe, but also from high MDR-
TB burden former Soviet Union states (Migliori 2009; Tiberi
2016). One of these also recruited from centres in South America,
with low tuberculosis burden andmixedMDR-TB burden (Tiberi
2016). One study was conducted in China (Zhang 2014), another
in India (Udwadia 2010), and two in South Africa (Seddon 2014;
Olayanju 2018); these three countries have high tuberculosis, tu-
berculosis/HIV and MDR-TB burden. Ferlazzo 2018 recruited
from Armenia (former Soviet Union country, previously on the
high MDR-TB burden list), India and South Africa.
All RCTs and non-randomized studies were conducted in high-
income or upper-middle-income countries except for those that
recruited in India, a lower-middle-income country.
The RCTs recruited between 2008 and 2011. There was a wide
time range amongst the cohort studies: seven of the 14 started
recruitment in 2009 or later and three completed recruitment in
2009, with the earliest starting in 1995 and the latest completing
in 2017.
Participants
Two studies included children only (Seddon 2014; Galli 2016).
Jensenius 2016 recruited participants of all ages. The remainder,
including both RCTs, were conducted in adults (four studies not
reporting ages (Migliori 2009; Kwak 2015; Van Altena 2015;
Guglielmetti 2017), we assumed to have mostly or exclusively
included adults).
Most studies included bothMDR- andXDR-TB cases. TwoRCTs
(Lee 2012; Tang 2015), one prospective cohort study (Olayanju
2018), and one retrospective cohort (Zhang 2014), included only
XDR-TB cases, and Jo 2014 and Jeong 2015 includedMDR cases
with at least fluoroquinolone resistance (including XDR). Half
(14/28) of the cases in Ferlazzo 2018 were XDR. The remaining
studies included a minority of cases with XDR.
Seddon 2014 included 16 (of 149 total) children with rifampicin-
monoresistant-tuberculosis, managed as MDR-TB. No other
studies reported participants with rifampicin-monoresistant-tu-
berculosis.
HIV infection status was reported in all but four studies. Eight
included participants with HIV infection; two RCTs (Lee 2012;
Tang 2015), excluded HIV-positive individuals; and three re-
ported no known HIV-positive participants, but with variable re-
porting of whether participants had been tested. Studies report-
ing on antiretroviral therapy (Padayatchi 2012; Seddon 2014), de-
scribed administration to most participants with HIV infection.
Interventions
Linezolid dose varied widely. Of the RCTs, Lee 2012 investigated
the effect of immediate versus delayed (two months after random-
ization) linezolid 600 mg daily initiation, with a second random-
ization point after sputum culture conversion to either continue
on 600 mg or take a reduced 300 mg daily. Padayatchi 2012 used
a dose of 600 mg daily and Tang 2015 used a high initial dose
(1200 mg), followed at four to six weeks by a planned reduction
to 300 mg or 600 mg daily. Amongst the non-randomized studies,
dosing ranged from 300 mg to 1200 mg daily, with inconsistent
reporting. Five non-randomized studies did not report a dosing
strategy. In several of the remaining studies, the numbers of par-
ticipants receiving each dose were not clear.
Duration of receipt of linezolid, where known (eight studies), was
for a mean or median of over 90 days. Five studies reported aver-
age duration of over 180 days, with four of these being over one
year. We did not know the duration of four studies; one RCT
(Tang 2015), administered linezolid until sputum culture conver-
sion from positive to negative; and Zhang 2014 reported admin-
istration for, ”at least one month“, without further detail.
It was not clear formost non-randomized studies whether linezolid
had been used from the commencement of MDR or XDR ATT,
or added later. Kwak 2015 reported that linezolid, in addition to
all XDR-TB cases, ”was added for patients refractory to at least 3-
6 months of medical treatment“ in those with MDR-TB.
Background regimens were mostly reported to be individualized
according to susceptibilities, clinical parameters and WHO guid-
ance, and often not reported in detail. Where reported, most par-
ticipants received fluoroquinolones, injectable drugs, ethionamide
or prothionamide, and para-aminosalicylic acid.
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Few studies reported place of treatment. Where reported, ATT
was said to be administered on an inpatient basis, at least initially,
with some describing continuation of therapy as an outpatient.
An exception, Ferlazzo 2018 described some participants receiving
outpatient therapy from the outset.
Four studies reported surgical resection being carried out in a mi-
nority of participants: Kwak 2015; Van Altena 2015; Jensenius
2016; and Tiberi 2016.
Follow-up
Of the threeRCTs, Lee2012 conducted follow-upuntil 12months
after completion of ATT, Padayatchi 2012 followed participants
until 12 months from commencement of ATT, and Tang 2015
reported follow-up until the end of treatment.
The cohort studies reported follow-up procedures incompletely.
Zhang 2014 followed participants until threemonths after discon-
tinuing linezolid (i.e. not to the end of ATT). Jeong 2015 followed
participants until the end of treatment. Guglielmetti 2017 aimed
to follow-up until 24 months after ATT completion, Ferlazzo
2018 until six months from commencement, and Olayanju 2018
reported monthly follow-up for the duration of hospital stay. Fol-
low-up duration and frequency were unclear for the remaining
studies (Migliori 2009; Udwadia 2010; Jo 2014; Seddon 2014;
Kwak 2015; Van Altena 2015; Galli 2016; Jensenius 2016; Tiberi
2016).
Outcome measures
Two RCTs (Padayatchi 2012; Tang 2015), reported the review’s
primary outcomes of all-cause and tuberculosis-associated death
and treatment failure. Padayatchi 2012 did not report cure, due
to follow-up not extending beyond 12 months, while Tang 2015
did. These RCTs also reported the review’s secondary outcomes of
treatment interrupted and treatment completed (the Padayatchi
2012 study did so for treatment of up to 12 months). Lee 2012
did not report these outcomes separately for participants receiving
immediate versus delayed linezolid, though apart from death (no-
one died in either arm), they would have been less informative
because there was only two months’ delay in commencement of
linezolid.
All three RCTs (Lee 2012; Padayatchi 2012; Tang 2015) reported
sputum culture conversion from positive to negative, but not as
stipulated in the review protocol (i.e. time to conversion).
Adverse events were reported by all RCTs, although Tang 2015 did
not distinguish serious adverse events from the others. Lee 2012
did not separate adverse events between immediate and delayed
linezolid groups.
Adverse events reporting in the non-randomized studies was vari-
able. Only six out of 14 studies reported, or provided following
our request to the authors, comparative total numbers of adverse
events experienced by those who received linezolid versus those
who did not (Seddon 2014; Kwak 2015; Galli 2016; Guglielmetti
2017; Ferlazzo 2018; Olayanju 2018). A further three reported
or provided a total frequency of adverse events for the linezolid-
receiving groups, but not for those who did not receive linezolid
(Jo 2014; Zhang 2014; Tiberi 2016). The remaining five studies
provided data on frequency of linezolid discontinuation or adverse
events, or both, attributed to linezolid only.
Excluded studies
We excluded 96 studies after review of the full texts (Figure 1).We
excluded 67 studies because they were neither a randomized study
nor cohort study; 26 did not describe any use of linezolid; and
one did not fit the population eligibility criteria of the review. We
excluded two studies due to absence of adverse events data. Full
details are given in the Characteristics of excluded studies section.
A further 23 remained unclassified, due to no response from study
authors following our requests for data. See the Studies awaiting
classification section for further details.
Risk of bias in included studies
We assessed risk of bias for the included RCTs using the Cochrane
‘Risk of bias’ assessment tool (Higgins 2011a).We assessed the risk
of bias in the cohort studies using ROBINS-I tool (Sterne 2016).
See the ‘Characteristics of included studies’ section,which includes
a ‘Risk of bias’ table for each included study. We summarized the
results of the ‘Risk of bias’ assessments across all included RCTs
in Figure 2 and non-randomized studies in Figure 3.
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Figure 2. Risk of bias in included RCTs
Figure 3. Risk of bias in included non-randomized studies
Most of the subheadings that follow address risk of bias in RCTs;
for non-randomized studies, see the subheading Other potential
sources of bias.
Allocation
Lee 2012 had low risk of bias for random sequence generation,
due to use of permuted block randomization. Padayatchi 2012
and Tang 2015 had unclear risk of bias as procedures were not
clearly described.
Padayatchi 2012 described adequate allocation concealment pro-
cedures, with resulting low risk of bias, whilst Lee 2012 and Tang
2015 did not report these, so risk of bias was unclear.
Blinding
Lee 2012 described blinding of laboratory personnel only, which
allowed outcomes other than the primary outcome of sputum cul-
ture conversion to be influenced by knowledge of the interven-
tion. We deemed this to represent an unclear risk of performance
bias. For detection bias, we judged the primary outcome to be
at low risk, but bias was unclear for other outcomes. Padayatchi
2012 reported appropriate blinding of participants and personnel
initially (low risk of performance bias), but at 20 weeks, unblind-
ing occurred, which may have affected measurement of outcomes
at 12 months, resulting in high risk of detection bias. Tang 2015
reported no blinding, so there was a high risk of performance and
detection bias.
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Incomplete outcome data
Lee 2012 had low loss to follow-up at four months (i.e. for the
primary outcome), but substantially higher at the end of planned
follow-up. We deemed it to be at low risk for the primary out-
come of sputum culture conversion but unclear for other out-
comes, because of the well-conducted nature of the study. Due to
a high proportion of loss to follow-up, without reasons for with-
drawal being clear or specified by intervention group, we deemed
Padayatchi 2012 to be at high risk of attrition bias. Loss to follow-
up was lower in Tang 2015, with specified, balanced reasons for
withdrawal, resulting in our judgement of low risk of bias.
Selective reporting
There was no evidence of selective reporting by Lee 2012, with
some elements of the original protocol and substantial additional
data being provided in a supplement. Padayatchi 2012 reported,
within the commentary study and the full study protocol and
report, available online, much more than expected from an RCT,
with no evidence of selective reporting. Though Tang 2015 did
not publish a separate protocol, all outcomes stated in themethods
section of the study were reported in the results.
Other potential sources of bias
RCTs
Padayatchi 2012 reported discordance of administration of the
study drug (linezolid) and placebo in at least 25% of participants,
found incidentally in the pharmacokinetics study nested within
the main study. Though not identified with certainty, the study
authors concluded, ”it appears that the mixing of tablets due to
sporadic, human error occurred at the clinical site on more than
one occasion over a long time period, rather than in the pharmacy.“
There was no other source of bias apparent for Lee 2012 or Tang
2015.
Non-randomized studies
The ROBINS-I assessment process judges risk of bias in seven
domains, resulting in an overall judgement of risk of bias corre-
sponding to the highest level of risk displayed in any one domain.
For example, if a study is judged to have a serious risk of bias in
one study domain, but low risk of bias in all others, the overall
risk of bias for the study will be serious.
Risk of bias within the seven domains, and overall, is displayed
for all 14 studies in Figure 3. We deemed overall risk of bias to be
critical for three studies (Udwadia 2010; Jo 2014; Zhang 2014)
and serious for the remaining 11 studies. We deemed all studies to
have serious risk of bias in measurement of outcomes, consistent
with mostly retrospective design, some with unpublished repur-
posed data on linezolid. We judged 13 of the 14 studies to have
serious risk of bias for confounding, which is again reflective of
the largely retrospective studies included. Twelve were at low risk
of bias for selection of participants into the study, and 12 were at
low risk of bias from deviations from intended interventions.
Effects of interventions
See: Summary of findings for the main comparison
Linezolid compared to no linezolid for drug-resistant pulmonary
tuberculosis
RCTs
Due to the significant discordance of study drug and placebo ad-
ministration in Padayatchi 2012, we deemed this study unsuit-
able for any analysis of intervention effect. This left two RCTs,
Lee 2012 and Tang 2015. As these did not provide comparable
outcome data, we were unable to meta-analyse their results.
Table 2 shows findings from Lee 2012, which reported no deaths
prior to or while receiving linezolid. Sputum culture conversion at
four months after randomization (the study’s primary outcome),
was reported to be higher for participants receiving linezolid imme-
diately versus those receiving linezolid after a delay of twomonths:
15 out of 19 versus 7 out of 20 (RR 2.26, 95% CI 1.19 to 4.28).
Cure (27/39 randomized), treatment failure (4/39), and treatment
interruption (7/39), were not disaggregated by timing of linezolid
introduction (Lee 2012). Permanent linezolid discontinuationwas
reported in seven out of 39 (17.9%) participants.
Table 3 summarizes findings fromTang 2015. This study reported
significantly higher cure (RR 2.36, 95% CI 1.13 to 4.90), and
lower failure (RR 0.26, 95% CI 0.10 to 0.70), in participants re-
ceiving linezolid, compared to those who did not. No significant
difference was reported in the proportions of participants with
outcomes of treatment completed, death or treatment interrupted,
between linezolid and control groups. Time to sputum culture
conversion was not reported in the way that we had planned to
analyze this outcome: 26 out of 33 (78.8%) of those receiving
linezolid had sputum culture conversion at 24 months; the cor-
responding figure for those who did not receive linezolid was 12
out of 32 (37.6%; Tang 2015). Treatment interruption, defined
in the paper as ”default“, was reported in four out of 33 of the
linezolid-receiving and three out of 32 of the control groups, re-
spectively. Linezolid was discontinued permanently in two out of
33 participants, though an undefined larger number had tempo-
rary linezolid interruptions.
With regards to adverse events, Lee 2012 reported 56 adverse
events in total, 33 of which they deemed serious (the second re-
port of this study reported another four serious adverse events, but
without a corresponding figure for non-serious adverse events).
The adverse events included 21 out of 39 instances of periph-
eral neuropathy, 7 out of 39 optic neuropathy and 7 out of 39
with myelosuppression (bone marrow suppression). Tang 2015
reported a significantly higher incidence of anaemia (17/33 versus
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2/32), nausea and vomiting (16/33 versus 3/32), peripheral neu-
ropathy (8/33 versus 1/32), and optic neuropathy (6/33 versus 0/
32), amongst participants in receipt of linezolid, compared with
controls. Confidence intervals were not provided for these results;
significance was reported on the basis of P values.
We undertook a sensitivity analysis of the death, cure and failure
outcomes for Tang 2015. Imputing worst-case and best-case out-
comes by linezolid administration for participants with incom-
plete data did not change the similar proportion of death in the
two groups. Cure remained higher and failure remained lower for
participants who received linezolid, albeit with a loss of statisti-
cal significance when worst-case scenario outcomes were imputed
(lower CI = 0.89 for cure, and upper CI 1.05 for failure). The
worst-case analysis assumes that all the missing participants in the
linezolid group did not achieve cure and failed therapy, and all the
missing participants not receiving linezolid achieved cure and did
not fail therapy (Table 4).
Non-randomized studies
Table 5 contains a summary of findings from the included non-
randomized studies, andTable 6 showsmore detailed adverse event
data from these studies. We did not plan primary and secondary
outcome data extraction and meta-analysis for non-randomized
cohorts.
Disaggregated data were available from 12 studies (639 partic-
ipants), on total number of ‘any’ or ‘serious’ adverse events or
linezolid discontinuation, amongst participants receiving line-
zolid (Migliori 2009; Jo 2014; Seddon 2014; Zhang 2014; Kwak
2015; Van Altena 2015; Galli 2016; Jensenius 2016; Tiberi 2016;
Guglielmetti 2017; Ferlazzo 2018; Olayanju 2018). Six studies
(487 participants), provided data for total number of ‘any’ or ‘seri-
ous’ adverse events amongst participants who did not receive line-
zolid (Seddon 2014; Kwak 2015; Galli 2016; Guglielmetti 2017;
Ferlazzo 2018; Olayanju 2018).
A total of 602 adverse events were reported from 426 participants
(from 8 studies), receiving linezolid. Among 478 participants (5
studies), who did not receive linezolid, there were 813 adverse
events. Fifty-seven serious adverse events occurred amongst 164
participants (7 studies), who received linezolid, and 47 serious
adverse events occurred in 270 participants (5 studies), who did
not receive linezolid.
Linezolid-attributed adverse events were reported in a total of 529
participants from 10 studies (Migliori 2009; Udwadia 2010; Jo
2014; Seddon 2014; Zhang 2014; Kwak 2015; Galli 2016; Tiberi
2016; Guglielmetti 2017; Olayanju 2018). These included 108
bone marrow-related (e.g. anaemia, thrombocytopaenia, leukope-
nia), and 110 neuropathic (peripheral or optic) events.
Clear information on the numbers of participants experiencing
adverse events was not available due to incomplete reporting, so
we could not ascertain proportions. Follow-up duration was also
not available for all participants, so we could not describe event
rates.
Linezolid was discontinued in 141 of 624 participants (22.6%; 11
cohorts).
D I S C U S S I O N
Summary of main results
Table 2 and Table 3 summarize findings from the two RCTs for
which we were able to assess intervention effect (104 participants),
Lee 2012 and Tang 2015, respectively. Table 5 and Table 6 include
a summary of adverse events findings from the 14 non-random-
ized studies (1678 participants; 2 prospective, 12 retrospective).
We were unable to generate pooled effect estimates using meta-
analysis due to heterogeneity of outcomes studied and reported.
Summary of findings for themain comparison provides a GRADE
assessment of outcomes from Tang 2015.
Settings varied: the RCTs were based in the Republic of Korea
(Lee 2012), and China (Tang 2015); three cohort studies recruited
in the Republic of Korea, five in Europe (one included a centre
in a former Soviet Union country), two from South Africa, one
each in China and India, and two from multiple heterogeneous
centres. Tang 2015, and seven of the 14 non-randomized studies,
commenced recruitment in 2009 or later.
Dosing and duration of linezolid in studies were variable, but
also reported incompletely. Five studies did not report dosing at
all. In the majority of the remainder it was not clear how many
participants received each reported dose. Lee 2012 used 600 mg
daily until a second planned randomization to continuing 600
mg or reducing to 300 mg daily. Tang 2015 used 1200 mg daily,
then at four to six weeks, all were reduced to 300 mg or 600
mg, until sputum culture conversion. Only eight of the 14 non-
randomized cohorts stated ameanormedianduration, all of which
were reported to be longer than 90 days. Incompleteness of these
data precluded comment on the effect of dose and duration of
linezolid on outcomes. Follow-up duration was variable, when
reported; nine of the 14 non-randomized studies did not report
follow-up duration.
Lee 2012 did not report data in a manner that permitted report-
ing of the primary outcomes of this review. However, their report-
ing of sputum culture conversion did permit comparison between
those receiving linezolid immediately versus those starting it two
months after randomization. Tang 2015 reported all of the re-
view’s primary and secondary outcomes, but reported sputum cul-
ture conversion in a way that made it difficult to compare directly
with the data for that outcome reported by Lee 2012. In both
studies, the group randomized to receive linezolid from the outset
achieved a significantly higher proportion of sputum culture con-
version from positive to negative at the time points specified by
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the study authors than the comparator group, who either started
linezolid late or were not given it at all.
Tang 2015 reported significantly higher cure and lower failure
amongst the linezolid-treated group than controls, with no other
significant differences in death, treatment completed and treat-
ment interruption. The differences in cure and failure became
insignificant when we performed worst-case sensitivity analysis,
though this method produces extreme effect estimates. Our level
of certainty in the evidence was very low for cure and failure, fol-
lowing downgrading for risk of bias, indirectness and imprecision,
as presented in Summary of findings for the main comparison.
Tang 2015 reported more anaemia, nausea, and vomiting, and
neuropathy events amongst participants in the linezolid group
compared with controls. Lee 2012 did not provide comparative
adverse event data for those receiving linezolid versus those who
did not. Linezolid was discontinued in seven out of 39 (17.9%)
participants in Lee 2012 and two out of 33 (6.1%) participants in
Tang 2015.
Where reported within the cohort studies, 141 out of 624 (22.6%;
11 cohorts), discontinued linezolid. We could not reliably com-
pare total adverse events, serious adverse events, and overall and
specific linezolid-attributed adverse events, but we have shown
these outcomes descriptively in Table 6. This is due to a lack of
data on follow-up duration and numbers of participants experi-
encing events.
Overall completeness and applicability of
evidence
Settings of the studies, in terms of tuberculosis incidence and drug-
resistant tuberculosis prevalence, were diverse. India was the only
lower-middle-income country (Udwadia 2010; Ferlazzo 2018),
with the remainder being upper-middle- or high-income coun-
tries. Children were included in three studies, two of which exclu-
sively recruited children (Seddon 2014; Galli 2016). Four non-
randomized studies did not report ages of their participants.
Reporting of linezolid dose and duration, and follow-up was vari-
able, as described in the Summary of main results and Table 1.
Seven cohort studies included participants with HIV, of which
two reported that most were taking antiretroviral therapy. Four
did not report HIV status, and three reported that no participants
were known to have HIV. The RCTs excluded people with known
HIV (Lee 2012; Tang 2015).
All participants in the Lee 2012 and Tang 2015 RCTs had XDR-
TB. Amongst the 12 cohorts contributing adverse events out-
come data disaggregated for linezolid receipt, 38.7% had XDR-
TB. Background regimens, where reported, were individualized
to drug susceptibility results, as per WHO guidance, in all of the
non-randomized studies, but one RCT, Tang 2015, used a speci-
fied universal regimen, whilst Lee 2012 reported a variety of back-
ground regimens. Thoracic surgical interventionswere undertaken
in a minority (< 25%) of participants, and proportions appeared
balanced between those who received linezolid and those who did
not, where reported.
This review highlights the lack of RCT evidence, with only one,
with no placebo or blinding, being suitable for analysis for primary
and secondary outcomes (Tang 2015), and the Lee 2012 RCT
providing limited comparative data for participants according to
receipt of linezolid. Outcome reporting was poor overall in the
non-randomized studies, which were included for adverse events
outcomes only. This means the evidence is neither complete, nor
widely applicable.
Certainty of the evidence
We were unable to find directly comparable RCT data, and had
planned, due to anticipated clinical and methodological hetero-
geneity, not to perform a meta-analysis on the data from non-
randomized studies. We did not therefore perform a meta-analy-
sis, but we have provided a GRADE assessment in Summary of
findings for the main comparison. This found very low certainty
in the evidence for all outcomes.
As we have described, we found significant problems with risk
of bias. We classified 11 of the non-randomized cohort studies
as having serious overall risk of bias, and three as having critical
overall risk of bias, using the ROBINS-I tool (Characteristics of
included studies; Sterne 2016).
Potential biases in the review process
We took measures to limit bias in the review process, by following
procedures outlined in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011b). The Cochrane Infectious
Diseases Group (CIDG) Information Specialist conducted the lit-
erature search. It is unlikely that the search missed major studies,
but some small unpublished studies may have been missed. We
did not make a funnel plot, as included studies did not provide
data suitable for meta-analysis. Two of the review authors exam-
ined the search results, determined study selection, and extracted
data independently, to minimize bias in study selection and data
extraction.
Agreements and disagreements with other
studies or reviews
We found five, previously published systematic reviews. These re-
views are summarized in Table 7. All of these reviews conclude that
linezolid is efficacious in the treatment of drug-resistant tubercu-
losis, although authors comment on the high likelihood of ad-
verse effects (Cox 2012; Sotgiu 2012; Chang 2013c; Zhang 2015;
Ahmad 2018). Three reviews used studies as the unit of analy-
sis, while two were individual patient data analyses. One review,
Ahmad 2018, reported a risk of bias assessment. Only one of the
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reviews included a RCT (Ahmad 2018), and only two included a
comparator group of people who did not receive linezolid (Chang
2013c; Ahmad 2018).
Cox 2012, Sotgiu 2012, and Zhang 2015 assessed treatment out-
comes and adverse events in 11 (148 participants), 12 (121 par-
ticipants), and 15 (367 participants) studies, respectively. Most
of these studies were case series in which all participants received
linezolid. Risk ratios could not be calculated due to the lack of
comparative adverse events data on participants who did not re-
ceive linezolid. Cox 2012 and Sotgiu 2012 concluded that line-
zolid was efficacious for drug-resistant tuberculosis, though both
advised caution in its use due to high incidence of adverse events.
Zhang 2015 suggested that linezolid was a ”promising option as
treatment of MDR/XDR TB“, but advised randomized studies to
define dosing.
Chang 2013c assembled a cohort from 20 studies reporting on the
then-named ”group 5“ anti-tuberculous drugs, including 194 par-
ticipants, of whom 162 received linezolid. They used a composite
”favorable outcome“ as the primary outcome, defined as ”sputum
culture conversion, cure, or treatment completion in the absence
of death, treatment interruption, treatment failure, or relapse.“
Random-effects meta-analysis of ”favorable outcome“ according
to linezolid use resulted in a pooled RR of 1.55 (95% CI 1.10 to
2.21), favouring linezolid. The outcomes in our review were not
reported separately by Chang 2013c; in particular, there was no
summary or meta-analysis of adverse events outcomes.
Ahmad and colleagues conducted an individual patient data meta-
analysis of 50 studies reporting treatment outcomes in drug-resis-
tant tuberculosis, including 39 studies reporting use of linezolid
(Ahmad 2018), of which one was a RCT included in our review
(Lee 2012). Their primary outcomes were treatment success and
death, with no summary of adverse events outcomes due to het-
erogeneity in measuring and reporting. The data were in favour
of treatment success with linezolid use (722/799) versus without
(5066/5864), with a crude odds ratio of 1.5 (95% CI 1.2 to 1.9),
adjusted odds ratio 3.4 (95% CI 2.6 to 4.5), and adjusted risk
difference 0.15 (0.11 to 0.18). Mortality was lower with linezolid
use (84/883) versus without (1456/7320), with a crude odds ra-
tio of 0.4 (95% CI 0.3 to 0.5), adjusted odds ratio 0.3 (95% CI
0.2 to 0.3), and adjusted risk difference −0.20 (95% CI −0.23
to −0.16). However, they found high heterogeneity (> 50%) in
the studies overall.WhenXDR-TB patients’ outcomes weremeta-
analysed separately, the effect estimates remained in favour of line-
zolid use, with low heterogeneity amongst these studies (< 10%).
Similar to our review, the authors highlighted a lack of data from
RCTs, prospective studies, and low- and middle-income settings
(Ahmad 2018).
Our proportion of linezolid discontinuation (22.6%) was lower
than the 36% pooled discontinuation found by Cox 2012, and
35% reported byZhang 2015. The other three previous systematic
reviews did not report discontinuation specifically.
When evidence for the use of linezolid was reviewed for the 2016
WHO guidelines (Annex 4 of WHO 2016a), the GRADE as-
sessment for Tang 2015 concluded moderate certainty in the ev-
idence for their comparison of treatment success versus a com-
posite outcome of failure/relapse/death in patients with XDR-TB.
They downgraded for serious risk of bias and imprecision, but up-
graded for a strong association. This is methodologically incorrect:
upgrading for strong association is only for observational studies
where GRADE starts as very low, and is not applicable to RCTs,
where GRADE starts as high (Guyatt 2011). The WHO 2016a
assessments for treatment success versus failure/relapse/death, and
death versus all other outcomes in patients with both MDR- and
XDR-TB, when Tang 2015 and six non-randomized studies were
combined, resulted in very low certainty. Our GRADE assess-
ment, with a population of MDR- and XDR-TB in mind, was
very low for all outcomes. This was in part due to downgrading
by one level for indirectness (the population in Tang 2015 was
limited to adults, with XDR-TB, without HIV co-infection, in
one country), and two levels each for risk of bias (no blinding, no
placebo, unclear randomization and allocation methods), and im-
precision (small sample size, and for most outcomes, low number
of events and wide CIs). We did not upgrade for a large effect size
(Summary of findings for the main comparison).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Two small randomized controlled trials (RCTs) in people with ex-
tensively drug-resistant tuberculosis (XDR-TB), reported better
efficacy outcomes with linezolid use. The first reported higher cure
(very low-certainty evidence), lower failure (very low-certainty
evidence), and higher sputum culture conversion at 24 months
(very low-certainty evidence), in participants who received line-
zolid compared with those who did not receive linezolid. The
second RCT reported higher sputum culture conversion rates at
four months for participants receiving linezolid immediately ver-
sus those who delayed initiation by two months. A lack of high-
quality, comparative evidence resulted in our inability to calculate
pooled effect estimates of efficacy and safety of linezolid, so we
cannot conclude implications for its use in all patients with drug-
resistant tuberculosis.
Implications for research
Whilst our review presents very low-certainty evidence for efficacy
of linezolid for XDR-TB, a lack of comparative design and report-
ing limits our certainty in the evidence for the use of linezolid in
all patients with drug-resistant pulmonary tuberculosis.
The safety of linezolid, in comparison with alternative or back-
ground regimens for drug-resistant pulmonary tuberculosis re-
mains unclear, even when previous reviews are consulted. In addi-
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tion, the questions of optimal dosing, duration and combination
therapy all remain unanswered, with the majority of existing com-
parative datasets coming from retrospective studies carried out in
high- and upper-middle-income countries.
RCTs in low- and lower-middle-income countries comparing line-
zolid-containing regimens with alternative regimens not contain-
ing linezolid would be desirable to inform guidance on its place in
management of drug-resistant pulmonary tuberculosis. Ongoing
studies may help, though they have not been designed to examine
linezolid’s efficacy and safety specifically, and are unlikely to report
before the next WHO guidelines are produced. In particular, we
would welcome improved, comparable safety reporting in drug
studies and observational studies, in order to answer difficult and
important questions relating to toxicity and tolerability of drug-
resistant tuberculosis treatments.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [author-defined order]
Lee 2012
Methods RCT of immediate and delayed (2 months from randomization) addition of linezolid
to an XDR-TB regimen. Laboratory assessors blinded to intervention status, but not
participants nor clinicians. No placebo used
Follow-up: weekly to 16 weeks, then monthly to 7 months, then 2-monthly to end of
treatment, then 6 months and 12 months after end of treatment
Loss to follow-up: at 12 months after end of treatment, 3 lost to follow-up, 8 withdrew
(including 4 failing therapy on linezolid)
Participants Setting: tertiary referral hospitals in SouthKorea:NationalMasanHospital inChangwon
and the National Medical Center in Seoul
Number of participants: 41 initially, of whom 21 randomized to receive immediate and
20 delayed linezolid. 2 did not receive linezolid in the immediate arm, so 19 reported
on in immediate group
Inclusion criteria
• Aged ≥ 20 years
• Pulmonary tuberculosis
• Radiographic evidence of lung tuberculosis
• Smear and culture positive
• Confirmed genotypic or phenotypic XDR-TB (definition below), or failure of
treatment despite susceptibility
• Failure to respond to 6 months of anti-tuberculosis regimen including active
agents
• Willingness to be inpatient until 2 consecutive negative smears, then weekly
follow-up tests/visits
Exclusion criteria
• Previous linezolid use
• Women who were pregnant, breastfeeding, or of childbearing potential and
unable to use contraception
• Men unwilling to use contraception
• Pre-existing low blood cell counts/renal failure/liver failure (see cut-offs in
protocol)
• History/presence of neuropathy, HIV infection or connective tissue disease
• Allergy or serious adverse reaction to linezolid
• Anticipated surgical intervention
• Use of antidepressants listed in protocol
HIV status: excluded people with HIV co-infection
Baseline drug susceptibilities: all had XDR-TB. The immediate group were resistant to
a mean 11.6 (range 8-15) anti-tuberculosis drugs tested. The delayed linezolid group
were resistant to mean 10.4 (range 6 to 14) anti-tuberculosis drugs tested
Interventions Planned linezolid regimen: started immediately or 2 months after randomization on 600
mg/day
After confirmed sputum-smear conversion or 4 months (whichever came first), partici-
pants underwent a 2nd randomization to continued linezolid therapy at a dose of 600
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Lee 2012 (Continued)
mg/day or 300 mg/day for additional ≥ 18 months
Median duration overall 781 days
33 in total underwent second randomization: 17 continued 600 mg/day, 16 switched to
300 mg/day
Background regimen: see Lee 2012 Supplemental Table 1 in the Supplementary Ap-
pendix for the article available at: www.nejm.org/doi/suppl/10.1056/NEJMoa1201964/
suppl file/nejmoa1201964 appendix.pdf. Unable to summarize due to heterogeneity of
timing of regimens and not stratified by immediate/delayed linezolid
Other interventions: not reported. Surgical candidates were excluded systematically
Outcomes Primary outcome
• Sputum culture conversion at 4 months from randomization. Culture on solid
medium used as primary outcome, but liquid medium also tested and reported
Secondary outcomes
• Pharmacokinetic analysis of linezolid on blood samples
• AEs
Notes Date: Recruitment December 2008 to May 2011
Authors: collaboration between authors based at recruiting centres, centrally in South
Korea, and international collaborators from Singapore and the USA
Study sponsors: supported by the Intramural Research Program, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, and by the Ministry of
Health and Welfare, South Korea
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Appropriate method of sequence genera-
tion: permuted-block randomization
Allocation concealment (selection bias) Unclear risk Allocation concealment not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Laboratory staff were unaware of alloca-
tion, but there was a risk of amending co-
interventions and dictating sputum collec-
tion by clinicians, though the effects may
be indirect
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Unclear risk for all but primary outcome
As laboratory staff were blinded from in-
tervention status, low risk for that outcome
assessment, but for others there might be a
higher risk of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk Unclear risk for all but primary outcome
For primary outcome, low loss to follow-
up
Further outcomes not reported separately
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for each group, and overall loss to follow-
up was much higher
Selective reporting (reporting bias) Low risk There is no evidence of selective reporting
Other bias Low risk No other source of risk of bias identified
Padayatchi 2012
Methods RCT, double-blind, placebo-controlled
Follow-up for 12 months: every 2 weeks until 16 weeks, then months 5, 6 and 12
Loss to follow-up of 31% (11/35), at median 15 days from start of study
Participants Setting: King George V Hospital, Durban, South Africa - public sector tertiary referral
hospital
Number of participants: 36; linezolid, 18 (16 analysed); no linezolid, 18
Inclusion criteria
• Pulmonary tuberculosis with/without extrapulmonary tuberculosis with a M
tuberculosis isolate confirmed resistant to at least rifampin and isoniazid (without regard
to prior treatment for tuberculosis)
• Documented positive sputum culture result forM tuberculosis from a sputum
obtained in the 4 months prior to enrolment
• Willingness to have HIV testing performed, if HIV serostatus unknown or if last
documented negative HIV test was > 6 months prior to enrolment
• Age > 18 years
• Karnofsky score > 40
• Willingness to attend scheduled follow-up visits and undergo study assessments
• Willingness of women with child-bearing potential to practice an adequate
method of birth control or to abstain from heterosexual intercourse during study
therapy. (Standard birth control measures provided free of charge by public health
institutions)
• Laboratory parameters within 14 days prior to screening:
◦ serum creatinine level < 2 times ULN
◦ haemoglobin level of > 9.0 g/dL
◦ platelet count > 80,000/mm3
◦ ANC > 1000/mm3
◦ negative pregnancy test (for women of childbearing potential)
• Able to provide informed consent or legally authorized representative able to do
so if decisionally impaired
Exclusion criteria
• Currently breast-feeding or pregnant
• Known allergy or intolerance to linezolid
• Planned therapy during the intensive phase of tuberculosis treatment using drugs
with unacceptable interactions with linezolid, including dopamine, selective serotonin
uptake inhibitors (citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline),
amitriptyline, bupropion, mirtazepine, levodopa, carbidopa, sinemet, or herbal
medications.
• Significant peripheral neuropathy as evidenced by < 5 seconds of vibratory sense
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Padayatchi 2012 (Continued)
to a 128 Hz tuning fork on either big toe when tested bilaterally
• Pain, aching or burning of the feet that interfere with walking or sleep
• Life expectancy < 4 weeks (in the judgment of the physician)
• Anticipated surgical intervention for the treatment of pulmonary tuberculosis
• Visual acuity of ≤ 20/200 (6/60 meters) best corrected vision
• Poor colour vision as evidenced by incorrect answers on > 4/12 screening Ishihara
plates
• Participation in another drug study
• Taken second-line tuberculosis drugs for > 14 days immediately prior to
enrolment (note: use of first-line drugs such as INH, Rifampin, PZA, or ethambutol
for > 7 days immediately prior to enrolment is allowed)
HIV status: linezolid: 9/18, 4 on antiretroviral therapy; no linezolid: 11/18, 8 on an-
tiretroviral therapy
Baseline drug susceptibilities: all MDR - no further details available
Interventions Planned linezolid regimen: 600mgonce daily for 16weeks, fromoutset ofMDR therapy;
control arm received placebo once daily for 16 weeks
Background regimen: individual regimens not stated, though some degree of individ-
ualization took place. The standard initial treatment regimen for MDR-TB consisted
of: 18-24 months ethionamide, kanamycin, pyrazinamide, ethambutol or cycloserine/
terizidone, and ofloxacin
The standard empirical XDR-TB regimen was: capreomycin, para-aminosalicylic acid,
ethambutol and/or cycloserine, and pyrazinamide
Therapy was administered for the initial 4 months as an inpatient, and then at home
with direct observation
Other interventions: pyridoxine was given to all participants
Outcomes Primary
• Tolerability: proportion of participants in each arm who take at least 80% of the
112 directly observed doses of study drug (i.e. at least 90 doses) within 18 weeks of
study treatment initiation
• Safety: cumulative rate of SAEs (number of SAEs per person days) during the
period of study drug therapy and the 4 weeks of post-study drug therapy follow-up.
Secondary
• Microbiological outcomes: including the proportion of culture-conversions at 2-
week intervals, time-to-conversion of cultures, and Mycobacterial Growth Indicator
Tube (MGIT) “time to detection,” during the first 16 weeks in the 2 study arms
• Microbiologic outcomes and survival rates in those treated with linezolid and
OBT vs those treated with OBT at 16 weeks and 5 months of therapy
• Determine the ability to identify and recruit eligible patients with MDR-TB and
XDR-TB treatment study, and to retain and follow them for up to 5 months
Notes Date: 14 April 2009 to 16 April 2010
Authors: TB Trials Consortium
Study sponsors: “The study was supported by funding by the US Centers for Disease
Control and Prevention (CDC) through theDivision of Tuberculosis Elimination. Line-
zolid was kindly donated by Pfizer Pharmaceuticals along with funding for the creation
of a placebo study drug and for conducting the pharmacokinetic analysis of linezolid.”
Discordance in blood linezolid detection in two participants in each arm - thought due
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Padayatchi 2012 (Continued)
to pill allocation (linezolid/placebo). Prompted investigation, finding around 25% of
participants had received incorrect pills
Full protocol available at: tbtrialsnetwork.org/wp-content/uploads/2014/09/Protocol-
TBTC-Study-30-Linezolid-MDR-XDR-TB.pdf
Full report available at: tbtrialsnetwork.org/wp-content/uploads/2014/09/Final-
Report-TBTC-Study-30-Linezolid-MDR-TB.pdf
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”The study will use unrestricted
randomization. The statistician will pre-
pare the randomization procedure and pro-
vide it to the research pharmacist.“
Comment: method of randomization not
described clearly
Allocation concealment (selection bias) Low risk Quote: ”The pharmacist will execute the
randomization procedure when a patient is
enrolled and will assign the study ID and
provide blinded medication to study per-
sonnel.“
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: ”Drugs provided during the ini-
tial phase of therapy will be mechanically
packaged by the study pharmacist and la-
beled similarly with patient name and ward
number by the site pharmacy using a label
printer.“
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blindingmaintained for 20weeks after ran-
domization but outcomes assessed at 12
months
Incomplete outcome data (attrition bias)
All outcomes
High risk 5/16 participants in linezolid arm and 4/
18 in the placebo group lost to follow-up.
Reasons for study withdrawal not clear, but
study authors present a table of presumed
reasons for withdrawal, although this is not
disaggregated by intervention group
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias High risk Study authors report that a nested pharma-
cokinetics study demonstrated that signifi-
cant numbers of participants in the placebo
group actually received linezolid, and sig-
nificant numbers of people in the linezolid
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Padayatchi 2012 (Continued)
group actually received placebo. Discor-
dance of study drug was found for 9/36
(25%) of participants overall
Tang 2015
Methods Multi-centre RCT; no blinding or placebo
Follow-up: “Patients underwent baseline and serial safety evaluations on a weekly basis
until the linezolid was reduced at 4-6 weeks, after which it was undertaken every 2 weeks
until the linezolid was stopped and then it was once a month.”
Loss to follow-up: linezolid 4/33; no linezolid 3/32; actually defined later as ”default“
Participants Setting: “Five large-scale TB specialised hospitals in China”
Number of participants: 65; linezolid 33; no linezolid 32
Inclusion criteria
• Aged 18 to 64 years
• Positive sputum cultures with an XDR strain
• Continuously smear-positive after using available chemotherapeutic options
during the previous ≥ 12 months
Exclusion criteria
• Allergic to linezolid
• Severe cardiovascular, liver, kidney or blood system disease or other serious
illnesses
• Mentally ill
• Pregnant or lactating women
• Positive HIV test result
• Unable to purchase linezolid for economic reasons
HIV status: no HIV-positive participants (positive HIV test was an exclusion criterion)
Baseline drug susceptibilities: all XDR
Interventions Planned linezolid regimen (added to background regimen in intervention arm; not in
control arm): “Start dose of 1200 mg linezolid per day for 4-6 weeks, after which they
continued taking linezolid at a dose of 300-600 mg per day in accordance with body
weight and tolerability. This continued until the patients provided two consecutive
negative sputum cultures during a 2-month period (taken at least 30 days apart)”
Background regimen: all received prothionamide, pyrazinamide, moxifloxacin or gati-
floxacin or levofloxacin, and para-aminosalicylic acid. Capreomycin or amikacin were
given to 55% in the linezolid arm and 53% in the control arm. Clofazamine was used
by 67% in the linezolid arm and 59% in the control arm. 55% in the linezolid arm and
52% in the control arm received clarithromycin
Other interventions: none reported
Outcomes Treatment outcomes, as defined by the WHO, were recorded
“Additionally, cured and completed treatment categories were combined as ‘treatment
success’, whereas others were combined as ‘poor treatment outcome’.”
AEs: including leukopenia, anaemia, peripheral neuropathy and optic neuropathy
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Tang 2015 (Continued)
Notes Date: October 2009 to August 2011
Authors: based at 6 specialist hospitals, and Shanghai Minhang Center for Disease Con-
trol and Prevention, Shanghai, China
Study sponsors: “Key Project of Chinese National Programs (grant No. 2009ZX10003-
017)”
Linezolid was not provided to participants free of charge, so those who could not afford
it were excluded
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization method not described
Allocation concealment (selection bias) Unclear risk Allocation concealment methods not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the linezolid arm 4/33 participants were
lost to follow-up, and 3/32 in the control
arm. Of these, 2 in each arm were due to
”economic problems“, and the other 3 (2
in the linezolid arm, and 1 in the control
arm) were due to AEs. All participants were
included in the analysis
Selective reporting (reporting bias) Low risk The study protocol was not available for
review. All outcomes stated in introduction
and methods section were reported
Other bias Low risk No other source of bias identified
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Migliori 2009
Methods Retrospective cohort study
Follow-up: specific details of follow-up methods not reported
Loss to follow-up: linezolid, 40/85 had no treatment outcome, 1 had interrupted treatment and 1 was transferred
out; no linezolid, not reported
Participants Setting: 21 hospitals in Belarus, Germany, Italy and Switzerland
Number of participants: total 195; linezolid, 85 (45 included in efficacy analysis, 85 included in safety and tolerability
analysis); no linezolid, 110
Inclusion criteria
• MDR/XDR culture confirmed
• Definitive treatment end-points recorded (cured, completed, died or failed)
Exclusion criteria
• Still on treatment at the time of the data collection (for efficacy analysis; not for safety and tolerability)
HIV status: not recorded
Baseline drug susceptibilities: linezolid, 75/85 MDR; 41/45 in the efficacy analysis; 10/85 XDR; 4/45 in efficacy
analysis. They had resistance to a mean of 1.5 second-line drugs. No linezolid, 102/110 MDR; 8/110 XDR; mean
resistance to 0.9 second-line drugs
Interventions Planned linezolid regimen: of 85, 28 received 600 mg once daily, and 57 received 600 mg twice daily. Mean (+/- SD)
duration was 222 +/- 249 days; median 93 days
The intended duration was 3 months in Belarus due to limited availability; other countries did not report an intended
duration
Background regimen: “In all countries, regimens to treatMDR/XDR-TB cases were tailored toDST results according
to WHO recommendations, using fluoroquinolones, injectable agents and other second-line oral agents.” Specific
regimens were not reported
Other interventions: none reported
Outcomes Safety and tolerability end-points included SAEs and AEs. SAE defined as any adverse reaction that resulted in
temporary or permanent discontinuation of linezolid, whereas AE required only dose adjustment and/or addition of
concomitant treatment
Efficacy end-points included time to andproportion of sputum smear and culture conversions, and treatment outcome
Notes Date: 2001-2007
Authors: TBNET Study Group
Study sponsors: “This study was supported by the current research funds of the participating institutions. The data
collection system was initiated in 1996 with funding obtained by the Italian Association of Hospital Pulmonologists
(AIPO) through a Ministry of Health/Superior Institute of Health grant (National TB Project, Grant No. 1, 641/
96). The study is partially funded by the European Respiratory Society as a Clinical Research Collaboration.”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Incomplete control of confounding variables
2. Selection of participants into the study: moderate
Possible influence of intervention and outcome on selec-
tion into the study
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3. Classification of interventions: serious
Some concerns about intervention status definition
4. Deviations from intended interventions: low
Unlikely deviation from usual practice
5. Missing data: serious
Lack of AE outcomes in those not receiving linezolid
6. Measurement of outcomes: serious
Multi-centre retrospective studywith outcome assessment
by treating physicians
7. Selection of the reported results: moderate
No selection evident, however no detailed protocol
Overall: serious
One or more domain judged to be serious
Udwadia 2010
Methods Prospective cohort study
Follow-up: specific follow-up methods not reported
Loss to follow-up: linezolid, 3/18; no linezolid, not reported
Participants Setting: tertiary private hospital Mumbai, India
Number of participants: total 78; linezolid, 18; no linezolid, 60
Inclusion criteria: consecutive participants with MDR- and XDR-TB
Exclusion criteria: none reported
HIV status: not reported
Baseline drug susceptibilities: linezolid, 11/18 had MDR, 7/18 had XDR
Interventions Planned linezolid regimen: 600 mg twice daily was given for a mean 20.6 months
Background regimen: this was individualized, but specific details were not reported
Other interventions: none reported
Outcomes Treatment outcomes and AEs were reported for those receiving linezolid
Notes Date: 2000 to 2007
Authors: based in the department of pulmonary medicine at the hospital in which the participants were treated
Study sponsors: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
No control for confounding
2. Selection of participants into the study: low
Unlikely to be selected with knowledge of the outcome
3. Classification of interventions: low
Intervention is well defined, and likely defined based on
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”information collected at the time of intervention“
4. Deviations from intended interventions: low
Likely to be similar to usual practice
5. Missing data: critical
Critical differences between groups in amount of data
provided
6. Measurement of outcomes: serious
”The outcome measure was subjective (i.e. vulnerable to
influence by knowledge of the intervention received by
study participants); and the outcome was assessed by as-
sessors aware of the intervention received by study partic-
ipants“
7. Selection of the reported results: no information
Not enough information
Overall: critical
One or more domain judged to be critical
Jo 2014
Methods Retrospective cohort study
Follow-up: no specific follow-up methods reported
Loss to follow-up: 4/70 participants were lost to follow-up; this was not stratified according to whether or not they
received linezolid
Participants Setting: Asian Medical Centre, Seoul, Korea - tertiary referral centre
Number of participants: 70 total; linezolid, 26; no linezolid, 44
Inclusion criteria
• Diagnosed with MDR-TB January 2006-December 2012, at Asan Medical Center
• Identified using MDR-TB register
Exclusion criteria
• Ofloxacin-sensitive isolate
• “treated with later-generation FQs [fluoroquinolones] that were added to an initial failed regimen due to the
unavailability of other effective drugs”
• “Another seven patients were excluded at the request of a pharmaceutical company sponsoring a clinical study
for a novel MDR-TB drug, in which these patients were enrolled”
HIV status: only 9/70 tested - all negative
Baseline drug susceptibilities: linezolid, 13/26 had XDR-TB; no linezolid, 13/44 had XDR-TB
Interventions Planned linezolid regimen: 16/26 received 300 mg/day; 10/26 received 600 mg/day. Duration ranged from 14-752
days; median was 258.5 (interquartile range 154.5-548) days
Background regimen: this was individualized according to drug susceptibility testing, and comprised a median 5
drugs. 54/70 received a later generation fluoroquinolone, and 2/70 received delamanid
Other interventions: surgical resection was performed in 16/70 participants
Outcomes Treatment outcomes, as defined by WHO: “cured, treatment completed, treatment failed, died, lost to follow-up
and not evaluated”
AEs, including discontinuation of linezolid, were also reported
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Notes Date: January 2006 to December 2012
Authors: based in the Department of Pulmonary and Critical Care Medicine, in Asan Medical Center, where the
participants were treated
Study sponsors: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
“At least one known important domain was not appro-
priately measured, or not controlled for”
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: moderate
Intervention groups were not defined well enough
4. Deviations from intended interventions: low
Likely to reflect usual practice
5. Missing data: critical
Critical differences in reporting of outcomes for those
receiving and not receiving linezolid, with no analysis to
correct for this
6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: serious
Lack of data for those not receiving linezolid
Overall: critical
One or more domain judged to be critical
Seddon 2014
Methods Retrospective review of register of children treated for MDR-TB
Follow-up: methods for follow-up not reported specifically
Loss to follow-up: 8/149 participants were lost to follow-up
Participants Setting: Tygerberg Hospital, Western Cape, South Africa - regional tertiary referral paediatric hospital
Number of participants: 149 in total; linezolid, 3; no linezolid, 146
Inclusion criteria
• Children < 15 years treated for MDR-TB (includes rifampicin monoresistant tuberculosis as per guidelines).
• “Children with confirmed and presumed MDR-TB were included. A presumed diagnosis was typically made
by the attending clinical team if the child had clinical symptoms, signs and radiology of TB with documented close
MDR-TB exposure, or whose condition was failing to respond to a first-line TB regimen with documented good
adherence.”
Exclusion criteria:
• “Children initially started on MDR-TB treatment due to MDR-TB exposure but those who were
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subsequently confirmed to have drug-susceptible TB were excluded from analysis.”
HIV status: 146 participants had known HIV status; linezolid, 1/3 had HIV co-infection; no linezolid, 31/143
participants had HIV co-infection
Baseline drug susceptibilities: linezolid, 1 had MDR, and 2 had XDR; no linezolid, 142/146 had MDR, and 4/146
XDR
Interventions Planned linezolid regimen: the 3 participants were treated for 4 months, 16 months and 21 months. The dose was
not reported
Background regimen: participants received individualized regimens. Most received isoniazid and ofloxacin. An in-
jectable agent was given in 94/149. 103/149 were admitted to hospital for 5 months; the rest treated at home
Other interventions: none reported
Outcomes “The most severe grade of adverse event experienced over the course of treatment, for each category, was determined.
MDR-TB treatment outcome was classified as cure, probable cure, treatment completed, failure, death, lost to follow-
up and transferred out.”
Notes Date: 2009 to 2012
Authors: included those based at Tygerberg Hospital, but also collaborators in London, UK
Study sponsors: “This research was supported by a United States Agency for International Development (USAID)
Cooperative Agreement (TREAT TB Agreement No. GHN-A-00-08-00004-00) (JAS and HSS), the Sir Halley
Stewart Trust (JAS) and the National Research Foundation of South Africa (HSS).”
All participants were children
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
No evidence of controlling for confounding
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: low
Intervention well defined, based on contemporaneous in-
formation
4. Deviations from intended interventions: low
Likely to reflect usual practice
5. Missing data: low
Data reasonably complete
6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: moderate
No evidence of selected reporting, but no detailed proto-
col
Overall: serious
One or more domain judged to be serious
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Methods Retrospective record review
Follow-up: this occurred “at least monthly”; “patients enrolled in this study only received less than 6 months LZD
[linezolid] treatment rather than ≥18-24 months. And the follow-up period for those patients was completed only
for 3 months after discontinuing LZD.”
Loss to follow-up: not reported
Participants Setting: Beijing Chest Hospital, Beijing, China (tuberculosis specialized hospital)
Number of participants: 43 in total; linezolid, 15; no linezolid 28
Inclusion criteria
• XDR-TB confirmed by culture and drug susceptibility testing
Exclusion criteria
• None reported
HIV status: “All… negative”
Baseline drug susceptibilities: all XDR; 81% resistant to para-aminosalicylic acid; 72% resistant to prothionamide;
77% resistant to ethambutol. “No statistical difference between LZDgroup and control groupwithout LZD regarding
the proportions of drug-resistant cases was detected (P>0.05).”
Interventions Planned linezolid regimen: 600 mg once daily, for ≥ 1 month
Background regimen: participants received unspecified “individualized treatment regimens”
Other interventions: none reported
Outcomes Sputum culture conversion: time; “favourable outcome” = 2 consecutive negative cultures; “adverse outcome” =
positive culture at the endpoint of treatment
AEs
Linezolid minimum inhibitory concentration (MIC) and genotypic resistance mutation determination
Notes Date: March 2012 to February 2013
Authors: some were based at the treating centre; others were at the National Center for Tuberculosis Control and
Prevention, Beijing, China
Study sponsors: “Supported by National Key Project (2013003ZX003)”
Not all could afford linezolid - not provided free of charge by the Chinese Government
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
No evidence of controlling for confounding
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: low
Intervention well defined, based on contemporaneous in-
formation
4. Deviations from intended interventions: low
Similar to usual practice
5. Missing data: critical
No AE outcome data for those not receiving linezolid
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6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: serious
Lack of methods on AE outcome measurement
Overall: critical
One or more domain judged to be critical
Jeong 2015
Methods Retrospective cohort study
Follow-up: “Sputum smear examinations and cultures were performed monthly for the first 6 months and then at 2
to 3 month intervals until the end of treatment.”
Loss to follow-up: 23/337 were lost to follow-up; no further details were provided on time of loss to follow-up or
breakdown by receipt of linezolid
Participants Setting: “Samsung Medical Center, a 1961 bed referral hospital in Seoul, Korea”
Number of participants: initially 337, but then analysis provided for the 144 who had fluoroquinolone resistance:
linezolid, 58; no linezolid, 86
Inclusion criteria
• Pulmonary MDR-TB
• also with fluoroquinolone resistance
Exclusion criteria
• “(i)…Transferred to our hospital after negative conversion of sputum culture with >3 months of treatment
with second-line drugs; (ii) … transferred to a national TB hospital after <3 months of treatment in our hospital;
and (iii) … treated for extra-pulmonary MDR-TB”
HIV status: “None of the patients was positive for HIV infection”
Baseline drug susceptibilities: all had fluoroquinolone-resistant MDR; linezolid, 30/58 (51.7%) had XDR-TB; no
linezolid 18/86 (20.9%) had XDR-TB
Interventions Planned linezolid regimen: 53/62 (note inconsistent denominator) received 300 mg once daily; 7/62 received 600
mg once daily; 2/62 had 600 mg initially followed by 300 mg once daily
Background regimen: individualized according to WHO guidelines. Drugs used within regimens:
• linezolid:
◦ injectable drug: 50/58 (86.2%)
◦ fluoroquinolone: 57/58 (98.3%)
◦ prothionamide: 19/58 (32.8%)
◦ cycloserine: 42/58 (72.4%)
◦ para-aminosalicylic acid: 23/58 (39.7%)
• no linezolid:
◦ injectable drug: 78/86 (90.7%)
◦ fluoroquinolone: 82/86 (95.3%)
◦ prothionamide: 64/86 (74.4%)
◦ cycloserine: 80/86 (93%)
◦ para-aminosalicylic acid: 51/86 (59.3%)
Other interventions: surgical resection; linezolid, 22/58; no linezolid 24/86
Outcomes Treatment outcomes according to 2013 WHO definitions
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Notes Date: January 2005 to December 2011
Authors: based at the institution treating the participants, without external collaborators
Study sponsors: grant of the Korean Health technology R&D Project, Ministry for Health & Welfare, Republic of
Korea (HI13C0871)
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: no information
No comparative AE data, so no confounding or control
for this would be relevant
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: moderate
“The addition of linezolid to the treatment regimen was
decided by the attending physician”
4. Deviations from intended interventions: low
Similar to usual practice
5. Missing data: no information
Reasons for missing data not provided
6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: low
Only 1 AE outcome reported, with no effect estimate
possible
Overall: serious
One or more domain judged to be serious
Kwak 2015
Methods Retrospective cohort study
Follow-up: no details of follow-up were reported
Loss to follow-up: 6 (4.8%) were lost to follow-up, including those not evaluated in the final analysis; no further
details were provided
Participants Setting: Seoul National University College of Medicine, a tertiary referral centre in Seoul, Korea
Number of participants: 123; linezolid 12; no linezolid, 111
Inclusion criteria
• MDR-TB
Exclusion criteria
• None reported
HIV status: not reported
Baseline drug susceptibilities: 123 MDR; 26 XDR, 13 quinolone-resistant (but not resistant to injectable drugs), 33
injectable-resistant (but not resistant to fluoroquinolones)
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Interventions Planned linezolid regimen: dose not reported, but “Linezolid was added for patients refractory to at least 3-6 months
of medical treatment and those who proved to have extensively drug-resistant [TB]”
Background regimen: “Although treatment for MDR-TB was individualised, the basic principles were based on
World Health Organization (WHO) recommendations.”
“MDR-TB patients were treated with a median of five drugs (IQR 5.0-6.0) for a median of 24.4 months (IQR 18.
4-27.3).”
113/123 (91.9%) received fluoroquinolones
90/123 (73.2%) received injectable drugs
Other interventions: “Surgical resection was considered for patients with localised lesions refractory to 3-6 months
of medical treatment.” This was carried out in 18 (14.6%) participants
Outcomes Treatment outcomes according to WHO criteria
A combined “unfavourable outcome” was determined: “Failed, died, defaulted and relapse patients comprised the
‘unfavourable outcomes’ group.”
Notes Date: 2006-2010
Authors: based at the institution managing participants, collaborating with authors from “Department of Internal
Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, Seoul”
Study sponsors: Seoul National University College of Medicine Research Fund, Seoul, Republic of Korea (grant
number 30-2013-0180). “The funders had no role in study design, data collection and analysis, decision to publish
or preparation of the manuscript. Statistical analysis was supported by the Medical Research Collaborating Center
(MRCC), Seoul National University College of Medicine.”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
No control for confounders for AE outcomes
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: low
Intervention well defined, based on contemporaneous in-
formation
4. Deviations from intended interventions: low
Similar to usual practice
5. Missing data: low
Data reasonably complete
6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: moderate
No evidence of selected reporting, but no detailed proto-
col
Overall: serious
One or more domain judged to be serious
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Methods Retrospective cohort study
Follow-up: not stated specifically, but some inpatient stay and then outpatient nurse supervision
Loss to follow-up: “Only 28/98 patients were consistently followed up for at least 24 months; 28 patients had zero
follow-up days after treatment discontinuation or completion, mainly because they left the country.” In addition, “2
defaulted/stopped treatment”
Participants Setting: 2 dedicated tuberculosis centres in the Netherlands - all MDR cases in the Netherlands are admitted there
Number of participants: 113 were enrolled; 104 started therapy, linezolid, 53; no linezolid 51
Inclusion criteria
• “All patients diagnosed with MDR-TB between January 2000 and December 2009. Patients diagnosed earlier
who started treatment during the study period were also included.”
• All participants had culture-confirmed tuberculosis
Exclusion criteria
• “Patients diagnosed in 2009 but who started treatment in 2010 were excluded”
HIV status: 14/113 were reported to have HIV infection; no breakdown by linezolid receipt status was reported
Baseline drug susceptibilities: 4/112 had XDR; remaining MDR. 10/112 were aminoglycoside-resistant, and 7/110
were resistant to a fluoroquinolone
Interventions Planned linezolid regimen: 300 mg twice daily; sometimes reduced based on therapeutic drug monitoring results
There was no stated timing in relation to commencement of tuberculosis therapy
Linezolid was given for a mean duration of 99 days (range 12-706), median 56 days [IQR 26-91]
Background regimen: individualized, with a wide variety of regimens being used
≥ 18 months in total, and ≥ 12 months after sputum culture conversion from positive to negative
Median 6 active drugs were used (IQR 5-6, range 3-10)
Other interventions: 8 had thoracic surgery
Outcomes • Treatment outcomes
• Drug discontinuation and related AEs
Notes Date: 2000 to 2009
Authors: from various institutions within the Netherlands
Study sponsors: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Inadequate controlling
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: serious
Intervention status was not well defined
4. Deviations from intended interventions: low
Similar to usual practice
5. Missing data: low
Paucity of outcomes data, but similar regardless of inter-
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vention group
6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: moderate
Paucity of outcomes data, but no clear active selection
Overall: serious
One or more domain judged to be serious
Galli 2016
Methods Retrospective cohort study
Follow-up: not reported
Loss to follow-up: not reported
Participants Setting: recruitment from national tuberculosis register - i.e. various settings within Italy
Number of participants: 11 had MDR-TB, linezolid, 5; no linezolid 6
Inclusion criteria
• Children (< 18 years) treated for active or latent tuberculosis
• Case recorded in Italian national tuberculosis register
Exclusion criteria:
• None reported
HIV status: not reported
Baseline drug susceptibilities: 1 participant receiving linezolid had XDR; the remainder were MDR
Interventions Planned linezolid regimen: not reported
Background regimen: not reported
Other interventions: none reported
Outcomes Descriptive study, collecting a wide range of demographic, treatment, AE and treatment outcome data
Notes Date: January 2010 to December 2012
Authors: various authors within Italy - no international collaborators
Study sponsors: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Inadequate controlling
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: serious
Intervention status was not well defined
4. Deviations from intended interventions: no infor-
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mation
Not enough information on interventions to judge this
5. Missing data: low
Data reasonably complete once authors provided addi-
tional data
6. Measurement of outcomes: serious
Participant outcome measure, determined by treating
clinicians
7. Selection of the reported results: moderate
No evidence of selected reporting, but no detailed proto-
col
Overall: serious
One or more domain judged to be serious
Jensenius 2016
Methods Retrospective cohort study
Follow-up: not reported
Loss to follow-up: 12/68 participants were lost to follow-up. Age 16-25 and illicit drug use were identified as
independent risk factors for loss to follow-up in a multivariate analysis
Participants Setting: “The university hospitals at Bergen, Oslo, Tromsø and Trondheim.” (Norway)
Number of participants: 89 participants were enrolled, 68 started treatment; linezolid, 52; no linezolid, 16. Note
denominators for proportions of participants vary between 89 and 68
Inclusion criteria
• Notified as having MDR-TB between 1999 and 2014
Exclusion criteria
• None reported
HIV status: 3/89 reported to have HIV infection
Baseline drug susceptibilities: 6/89 participants had XDR-TB; the remainder had MDR
Interventions Planned linezolid regimen: “Usually 600mg twice a day”; no planned duration or timing in relation to commencement
of drug-resistant tuberculosis therapy
Background regimen: 65/68 received an injectable; 63/68 received a fluoroquinolone; 59/64 had direct observation
of therapy at home on discharge from hospital
Other interventions: 2 participants had lung resection surgery (both XDR)
Outcomes • Treatment outcomes
• Drug discontinuation (serious adverse drug effect recorded if prompted this)
Notes Date: 1995 to 2014
Authors: collaborators within Norway
Study sponsors: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Inadequate controlling
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: serious
Intervention status was not well defined
4. Deviations from intended interventions: low
Similar to usual practice
5. Missing data: no information
Not enough outcomes data to judge this
6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: moderate
No evidence of selected reporting, but no detailed proto-
col
Overall: serious
One or more domain judged to be serious
Tiberi 2016
Methods Retrospective cohort study
Follow-up: details of follow-up not reported
Loss to follow-up: in the 2 studies feeding into this cohort, treatment interruption was reported as 21/264 (8%) and
11/140 (7.9%)
Participants Setting: hospital inpatients in multiple centres in Belarus, Belgium, Brazil, Ecuador, Greece, Holland, Italy, Peru,
Slovakia, and UK
Number of participants: linezolid, 267; no linezolid, 81
Inclusion criteria:
• “Only adults with a culture-confirmed diagnosis of MDR-TB (i.e. tuberculosis caused by M tuberculosis
isolates resistant to at least isoniazid and rifampicin) were enrolled”
Exclusion criteria
• “Individuals aged <15 years were excluded.”
HIV status: in the 2 studies, 13/251 (5.2%) and 10/173 (5.8%) were reported to have HIV infection
Baseline drug susceptibilities: in the first study, 57/264 (21.6%) were XDR, 73/255 (28.6%) fluoroquinolone-
resistant, and 25%-33% resistant to the injectables amikacin, capreomycin or kanamycin. In the second study, 104/
180 (57.8%) were XDR, 110/175 (62.9%) fluoroquinolone-resistant, and 49%-61% resistant to injectables
Interventions Planned linezolid regimen: this was variable, ranging from 300 mg once daily to 600 mg twice daily
Background regimen: the majority received a fluoroquinolone (mostly moxifloxacin), and only < 10% received
bedaquiline or delamanid
Other interventions: in the first study, surgery took place in 21/257 (8.2%) and antiretrovirals were used in 11/13
(84.6%) of those with HIV infection. In the second study, 32/176 (18.2%) had surgery and 8/10 (80%) received
antiretrovirals
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Outcomes Treatment outcomes and AEs
Notes Date: 2003 to 2015
Authors: multinational collaboration, including clinicians looking after participants in treating centres
Study sponsors: none
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Inadequate controlling
2. Selection of participants into the study: low
Probably selected without bias, and follow-up started
when intervention started
3. Classification of interventions: serious
Intervention status was not well defined
4. Deviations from intended interventions: low
Similar to usual practice
5. Missing data: no information
Not enough outcomes data to judge this
6. Measurement of outcomes: serious
Subject outcome measure, determined by treating clini-
cians
7. Selection of the reported results: moderate
No evidence of selected reporting, but no detailed proto-
col
Overall: serious
One or more domain judged to be serious
Guglielmetti 2017
Methods Retrospective cohort study
Follow-up: during treatment then 24 months after if possible. Frequency not reported
Loss to follow-up: at end of treatment, 5/45; at 12 months after treatment, 9/36; at 24 months after treatment, 2/23
Participants Setting: multiple referral centres in France - hospitalized and treated for free
Number of participants: linezolid, 43; no linezolid, 2
Inclusion criteria
• “All MDR-TB patients treated with bedaquiline from January 1, 2011 to December 31, 2013 and hospitalised
at three French referral TB centres (Bligny, Pitié Salpêtrière and Bichat Hospitals).”
Exclusion criteria:
• None reported
HIV status: 2/45 reported to have HIV infection
Baseline drug susceptibilities: 24/45 (53%) had XDR-TB, 11/45 (24%) had fluoroquinolone-resistant MDR-TB,
and 6/45 (13%) had MDR-TB with additional resistance to injectable drugs. Only 4/45 had MDR-TB without
resistance to fluoroquinolones or injectables
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Interventions Planned linezolid regimen: 600 mg daily
Background regimen: all 45 received bedaquiline, 35/45 (78%) an injectable, 32/45 (71%) a fluoroquinolone, 40/
45 (89%) para-aminosalicyclic acid, 11/45 (24%) ethionamide, 32/45 (71%) cycloserine, 20/45 (44%) clofazimine,
and 28/45 (62%) imipenem/clavulanate
Other interventions: “Lung surgery, mostly lobectomy, was performed in 12 (26.7%) patients after a median (IQR)
of 170 (75-269) days from treatment start and after sputum culture conversion in 75% of cases.”
Outcomes “At the end of treatment, favourable outcomes were defined as the sum of cured and treatment completed; all other
outcomes were defined as unfavourable.”
AEs
Notes Date: 2011 to 2013
Authors:multicentre collaborators from various centres in France, including those based at sites recruiting participants
Study sponsors: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Inadequate controlling
2. Selection of participants into the study: low
Probably selected without bias, though information on
start of follow-up and start of intervention not clear
3. Classification of interventions: low
Intervention status well defined, though post-hoc
4. Deviations from intended interventions: low
Similar to usual practice (retrospective)
5. Missing data: low
Outcomes data available for nearly all participants
6. Measurement of outcomes: serious
Potential subjectivity of outcome measures, determined
by treating clinicians
7. Selection of the reported results: no information
Not enough information reported on outcome measure-
ment or analysis
Overall: serious
One or more domain judged to be serious
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Methods Multicentre retrospective cohort study of patients receiving bedaquiline and delamanid in combination
Follow-up: lab tests “at least monthly”. ECG every 2 weeks for first 3 months, then monthly. Follow-up results
reported up to 6 months
Loss to follow-up: at 6 months, 1/28 (participant had been culture-positive at 5 months)
Participants Setting: “Primary” and hospital care, various sites in Armenia (25% participants), India (25%), South Africa (50%)
Number of participants: 28; linezolid, 23; no linezolid, 5
Inclusion criteria
• MDR-TB
• Started on bedaquiline and delamanid for at least 1 week
• “Patients were eligible to receive the combination if a regimen with at least four other effective drugs could not
be constructed because of confirmed drug resistance, suspected resistance in the setting of previous drug exposure,
drug intolerance, or a combination of these three factors.”
Exclusion criteria
• Not reported
HIV status: 10/23 and 1/5 had HIV co-infection
Baseline drug susceptibilities: overall: 14/28 had XDR, 2/28MDR with additional injectable resistance, 10/28MDR
with additional fluoroquinolone resistance, 2/28 MDR
Interventions Planned linezolid regimen: not reported
Background regimen: all received bedaquiline and delamanid, 19/28 had clofazimine, 6/28 moxifloxacin and 15/28
carbapenems
Other interventions: not reported
Outcomes Efficacy
• sputum culture conversion at 6 months
• culture positivity/negativity at 6 months, regardless of baseline status
Safety
• SAE occurring within 6 months,
• Prolonged QTc
Tolerability
• Retention in care at 6 months
Notes Date: January to August 2016
Authors: members of South African, French, Armenian and Indian Médecins Sans Frontières units, and researchers
in South Africa and the USA
Study sponsors: Médecins Sans Frontières
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Lack of controlling for confounding
2. Selection of participants into the study: low
Probably selected without bias, though information on
start of follow-up and start of intervention not clear
3. Classification of interventions: low
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Intervention status well defined and collected program-
matically, though post-hoc data received
4. Deviations from intended interventions: low
Similar to usual practice (retrospective) with robust fol-
low-up plans
5. Missing data: low
Outcomes data available for nearly all participants
6. Measurement of outcomes: serious
Assessors of AEs likely to be aware of linezolid use and
may have been influenced in judging outcomes
7. Selection of the reported results: moderate
Relatively well defined outcome measurements, with
post-hoc linezolid-specific analysis
Overall: serious
One or more domain judged to be serious
Olayanju 2018
Methods Prospective cohort study
Follow-up: monthly sputum smear and culture during hospital stay, less frequently thereafter; treated for 24 months
Loss to follow-up: 30/272 (11%)
Participants Setting: Brooklyn Chest Hospital - Western Cape referral centre, Cape Town, South Africa
Number of participants: linezolid, 55; no linezolid, 217
Inclusion criteria
• Initiated treatment for culture confirmed XDR-TB
Exclusion criteria
• None reported
HIV status: 22/55 (40%) receiving linezolid and 101/217 (47%) who did not receive linezolid had HIV co-infection
Baseline drug susceptibilities: all had XDR-TB
Interventions Planned linezolid regimen: not reported
Background regimen:
• linezolid; all received bedaquiline, 1/55 an injectable, 54/55 a fluoroquinolone, 52/55 para-aminosalicylic
acid, 51/55 terizidone, 53/55 pyrazinamide, 15/55 ethambutol and 54/55 clofazimine
• no linezolid; 13/217 received bedaquiline, 209/217 an injectable, 205/217 a fluoroquinolone, 206/217 para-
aminosalicylic acid, 211/217 terizidone, 214/217 pyrazinamide, 200/217 ethambutol and 78/217 clofazimine
Other interventions: not reported
Outcomes Treatment outcomes: “…cure/treatment completion, deceased, treatment failure, treatment default and lost to follow-
up. Patients who achieved cure/completion were said to have had a favourable outcome while the deceased, defaulted
and those who failed treatment were said to have had unfavourable outcomes.”
AEs
Notes Date: Jan 2008-June 2017
Authors: based at the centre and affiliated university in Cape Town
Study sponsors: European Union (European and Developing Countries Clinical Trials Partnership: TESA, Oppen-
heimer Foundation, South African Medical Research Council and South African National Research Foundation)
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Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk ROBINS-I assessment:
1. Confounding: serious
Inadequate controlling of confounding
2. Selection of participants into the study: low
Prospective recruitment should avoid selection bias
3. Classification of interventions: low
Intervention status well defined
4. Deviations from intended interventions: serious
Background regimen differed significantly between the
groups
5. Missing data: low
Outcomes data available for nearly all participants
6. Measurement of outcomes: serious
Potential subjectivity of outcome measures, determined
by treating clinicians, though exact procedures not re-
ported
7. Selection of the reported results: low
No evidence of multiple outcome measurements or anal-
yses
Overall: serious
One or more domain judged to be serious
Abbreviations: AE: adverse event; ANC: absolute neutrophil count; DST: drug susceptibility testing; ECG: electrocardiogram; INH:
isoniazid;M tuberculosis:Mycobacterium tuberculosis; MDR: multi-drug resistant; OBT: optimized background therapy; PZA: pyraz-
inamide; QTc: corrected Q-T interval on electrocardiography; RCT: randomized controlled trial; SAE: serious adverse event; SD:
standard deviation; TB: tuberculosis; ULN: upper limit of normal; WHO: World Health Organization; XDR: extensively drug
resistant.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbate 2007 Not a trial/cohort study
Abbate 2010 Not a trial/cohort study
Aggarwal 2009 Not a trial/cohort study
Altet 2013 Not a trial/cohort study
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Anger 2010 Not a trial/cohort study
Bang 2010 Not a trial/cohort study
Berry 2016 Not a trial/cohort study
Bolhuis 2012 Not a trial/cohort study
Bolhuis 2015 Not a trial/cohort study
Cadena 2009 Not a trial/cohort study
Carroll 2011 Ineligible population
Chan 2013 Not a trial/cohort study
Chang 2012 Not a trial/cohort study
Chang 2013 Not a trial/cohort study
Cherenko 2013 Not a trial/cohort study
Coban 2009 Not a trial/cohort study
Coleman 2014 Not a trial/cohort study
Conradie 2014 No linezolid use
Corpe 1964 Not a trial/cohort study
Cox 2013 Not a trial/cohort study
Dauby 2011 Not a trial/cohort study
De Lorenzo 2012 Not a trial/cohort study
De Lorenzo 2013 Not a trial/cohort study
Dheda 2017 No linezolid use
Dhingra 2008 No linezolid use
Diacon 2012 No linezolid use
Farshidpour 2013 Not a trial/cohort study
Fattorini 2012 No linezolid use
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Fortun 2005 Not a trial/cohort study
Griffith 2004 Not a trial/cohort study
Gunther 2015 No linezolid use
Henry 2016 Not a trial/cohort study
Heyckendorf 2018 Lack of adverse event outcomes
Huang 2012 Not a trial/cohort study
Hughes 2015 Not a trial/cohort study
Jaramillo 2013 Not a trial/cohort study
Jaspard 2017 Not a trial/cohort study
Jiang 2013 No linezolid use
Joseph 2011 No linezolid use
Kjollerstrom 2011 Not a trial/cohort study
Koh 2009 Not a trial/cohort study
Koh 2012 Not a trial/cohort study
Lai 2008 No linezolid use
Laniado-Laborin 2012 Not a trial/cohort study
Maartens 2015 Not a trial/cohort study
Macedo 2012 Not a trial/cohort study
Maimakov 2013 No linezolid use
Manfredi 2009 Not a trial/cohort study
Milanov 2015 No AE outcomes reported
Mirsaeidi 2005 No linezolid use
Moyo 2015 No linezolid use
Nam 2009 Not a trial/cohort study
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Nie 2013 Not a trial/cohort study
O’Donnell 2013 No linezolid use
Palmero 2004 No linezolid use
Palmero 2010 Ineligible population
Palmero 2015 Not a trial/cohort study
Park 2004 No linezolid use
Park 2006 Not a trial/cohort study
Park 2010 Not a trial/cohort study
Pasticci 2012 No linezolid use
Pawar 2009 Not a trial/cohort study
Pietersen 2014 No linezolid use
Prajapati 2017 Not a trial/cohort study
Ralli 2011 Not a trial/cohort study
Roongruangpitayakul 2013 Not a trial/cohort study
Rose 2012 Not a trial/cohort study
Schecter 2010 Not a trial/cohort study
Seddon 2012 No linezolid use
Shah 2011 Not a trial/cohort study
Singla 2012 Not a trial/cohort study
Slebos 2004 Not a trial/cohort study
Sokolova 2008 No linezolid use
Sotgiu 2015 Not a trial/cohort study
Stoltz 2017 Not a trial/cohort study
Tabarsi 2010 No linezolid use
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Tang 2011 Not a trial/cohort study
Tang 2012 Not a trial/cohort study
Tangg 2011 Not a trial/cohort study
Tiberi 2016b No linezolid use
Tortoli 2010 No linezolid use
Tse-Chang 2013 Not a trial/cohort study
Udwadia 2017 Not a trial/cohort study
Van der Walt 2013 No linezolid use
Van Heurck 2013 Not a trial/cohort study
Velasquez 2014 No linezolid use
von der Lippe 2006 Not a trial/cohort study
Ward 2005 No linezolid use
Wirth 2017 Not a trial/cohort study
Xu 2012a Not a trial/cohort study
Xu 2012b No linezolid use
Yao 2011 Not a trial/cohort study
Yew 2008 Not a trial/cohort study
Yew 2009 Not a trial/cohort study
Yew 2014 Not a trial/cohort study
Yi 2017 Not a trial/cohort study
AE: adverse effects
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Characteristics of studies awaiting assessment [ordered by study ID]
Agarwal 2005
Methods Comparative study; unclear if retrospective or prospective
Participants 81 patients with MDR-TB
Interventions ”Study group treated with linezolid, clarithromycin, capreomycin, pyrazinamide, ethambutol and ethionamide.
Control group, treated with streptomycin, pyrazinamide, ethambutol and ethionamide. The course of treatment was
18 months. Linezolid was given for 6 months and aminoglycosides (capreomycin/streptomycin) for 10 weeks.“
Outcomes Sputum conversion (not stated if smear or culture), radiological improvement, closure of lung cavities, AEs
Notes Only the abstract was available for assessment, which lacked key elements required for classification. When contacted
for further data, there was no response from the study authors
Agarwal 2007
Methods Comparative study; unclear if retrospective or prospective
Participants 92 patients aged 18-50 years with MDR-TB; ”HIV negative, smear-positive, non-pregnant and had been receiving
anti-TB drugs for an average of 76 weeks (32 to 132 weeks).“
Interventions Study group treatedwith ”linezolid, azithromycin alongwith kanamycin, pyrazinamide, ethionamide and ethambutol
under direct supervision.“
Control group ”were given kanamycin, pyrazinamide, ethionamide and ethambutol.“
”Linezolid was given in the dose of 600mg once a day for 6 months. Kanamycin was given in the dose of 25 mg/kg
body weight on alternate days for 24 weeks. Pyrazinamide was given for full course of therapy.“
Outcomes Sputum conversion (not stated if smear or culture), radiological improvement, closure of lung cavities, AEs
Notes Only the abstract was available for assessment, which lacked key elements required for classification. When contacted
for further data, there was no response from the study authors
Anderson 2013
Methods ”Retrospective-prospective cohort study“
Participants People with MDR-TB
Interventions Individualized ATT; some of the cohort received linezolid
Outcomes Treatment outcomes, and risk factors associated with these
Notes 8 of the participants received linezolid, but outcomes were not stratified by receipt of linezolid within the publication.
Contact with the corresponding author was not possible, despite multiple attempts
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Methods Retrospective cohort study
Participants 100 consecutive cases of MDR-TB
Interventions Individualized ATT; some of the cohort received linezolid
Outcomes Treatment outcomes; treatment modalities; hospital admission
Notes 35 of the participants received linezolid, but outcomeswere not stratified by receipt of linezolidwithin the publication.
The study authors, when contacted, were unable to provide sufficient data to enable classification
Bionghi 2017
Methods Retrospective cohort study
Participants 153 rifampicin-monoresistant-, MDR- and XDR-TB cases
Interventions ”24 patients were initiated on Bedaquiline and 129 on Bedaquiline and Linezolid containing regimens.“
Outcomes Treatment outcomes, sputum culture conversion
Notes 129/153 participants received linezolid, but outcomeswere not stratified by receipt of linezolidwithin the publication.
When contacted for further data, there was no response from the study authors
Borisov 2017
Methods Retrospective cohort study
Participants ”428 culture-confirmed MDR-TB cases“
Interventions Individualized ATT: ”Treatment regimens included, among others, linezolid, moxifloxacin, clofazimine and car-
bapenems (82.0%, 58.4%, 52.6% and 15.3% of cases, respectively).“
Outcomes Sputum smear and culture conversion; treatment outcomes; AEs
Notes 82% of the participants received linezolid, but outcomes were not stratified by receipt of linezolid within the
publication. When contacted for further data, there was no response from the study authors
Catho 2015
Methods Retrospective cohort study
Participants ”Twenty-three consecutive adult MDR TB patients“
Interventions Individualized ATT; most received amikacin, a fluoroquinolone, para-aminosalicylic acid and linezolid
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Outcomes Treatment outcomes; AEs
Notes 18 of the participants received linezolid, but outcomeswere not stratified by receipt of linezolidwithin the publication.
When contacted for further data, there was no response from the study authors
Dey 2015
Methods Retrospective cohort study
Participants Children with drug-resistant tuberculosis
Interventions ATT, but the abstract does not include much further detail on interventions
Outcomes AEs
Notes Only the abstract was available for assessment, which lacked key elements required for classification. The study author,
when contacted, was unable to provide sufficient data to enable classification
Ganatra 2017
Methods Retrospective cohort study
Participants 20 clinical profiles of 45 linezolid-resistant cases, of whom 14 ”had prior exposure to linezolid“
Interventions ATT, but the abstract does not include much further detail on interventions
Outcomes Risk factors for resistance
AEs
Notes Only the abstract was available for assessment, which lacked key elements required for classification. When contacted
for further data, there was no response from the study authors
Grard 2015
Methods Retrospective cohort study
Participants 30 people with MDR-TB; 23 received linezolid
Interventions Individualized ATT; most received a fluoroquinolone, amikacin or streptomycin, cycloserine or para-aminosalicylic
acid
Outcomes Time to sputum culture conversion; treatment outcomes; AEs; pharmacokinetic data
Notes 23 of the participants received linezolid, but outcomes were only reported for those receiving linezolid within the
publication. When contacted for further data, there was no response from the study authors
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Jeon 2009
Methods Retrospective cohort study
Participants 176 people with XDR-TB
Interventions Individualized ATT
Outcomes Treatment outcomes, with composite ”favorable“ and ”unfavorable“ outcomes; mortality
Notes 7 of the participants received linezolid, but outcomes were not stratified by receipt of linezolid within the publication.
When contacted for further data, there was no response from the study authors
Kim 2007
Methods Retrospective cohort study
Participants 211 people with MDR-TB (20% XDR)
Interventions Individualized ATT; most received a fluoroquinolone, and injectable, para-aminosalicylic acid, cycloserine and pro-
thionamide
Outcomes Treatment outcomes; AEs
Notes 3 of the participants received linezolid, but outcomes were not stratified by receipt of linezolid within the publication.
When contacted for further data, there was no response from the study authors
Kim 2018
Methods Retrospective cohort study
Participants 61 people with pulmonary MDR-TB
Interventions All received delamanid and/or bedaquiline in a regimen with median 5 drugs; the following drugs were each present
in > 50% of regimens: an injectable, a fluoroquinolone and linezolid
Outcomes Treatment outcomes, AEs
Notes 33 of the participants received linezolid, but outcomeswere not stratified by receipt of linezolidwithin the publication.
When contacted for further data, there was no response from the authors
Kuksa 2017
Methods Retrospective cohort study
Participants 19 patients with MDR- or XDR-TB
Interventions All received delamanid within a programmatic optimized background regimen
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Kuksa 2017 (Continued)
Outcomes Treatment outcomes
Notes 14 of the participants received linezolid, but outcomeswere not stratified by receipt of linezolidwithin the publication.
When contacted for further data, there was no response from the study authors
Lee 2017
Methods Retrospective cohort study
Participants 76 participants with rifabutin-sensitive MDR-TB
Interventions Individualized ATT; most received a fluoroquinolone, an injectable and cycloserine
Outcomes Treatment outcomes
Notes 17 of the participants received linezolid, but outcomeswere not stratified by receipt of linezolidwithin the publication.
The study authors, when contacted, were unable to provide sufficient data to enable classification
Mehta 2016
Methods Retrospective cohort study
Participants 136 people initiating drug-resistant tuberculosis treatment
Interventions ATT, but the publication does not include much further detail on interventions
Outcomes Optic neuropathy in those receiving linezolid
Notes AEoutcomedatawere limited to those concerning ocular symptoms and signs, and only reported for those participants
receiving linezolid. The study authors, when contacted, were unable to provide sufficient data to enable classification
Meressa 2015
Methods Prospective cohort study
Participants ”All patientswithMDR-TB...Additionally, patientswith rifampicin-monoresistance or thosewith clinically presumed
MDR TB, based on multiple treatment failures despite directly observed therapy (DOT), or those who were close
contacts of patients with MDR TB, were also eligible for treatment.“
Interventions ATT: ”(1) at least three oral agents to which the patient was presumed to have susceptibility (eg, levofloxacin,
ethionamide, cycloserine or para-aminosalicylic acid (PAS)), (2) pyrazinamide and (3) an aminoglycoside (amikacin or
kanamycin) or polypeptide (capreomycin) injectable agent. Injectables were maintained for a minimum of 8 months
based on clinical, microbiological and radiographic evolution, and ultimate treatment duration was a minimum of
18 months after bacteriological conversion.“
Outcomes Treatment outcomes; AEs
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Notes Some (< 6) of the participants received linezolid, but outcomes were not stratified by receipt of linezolid within the
publication. When contacted for further data, there was no response from the study authors
Pang 2017
Methods Retrospective cohort study
Participants 29 people with ”XDR-TB-Plus“, i.e. XDR plus additional resistance
Interventions Individualized ATT, average 4.4 drugs; > 50% received each of moxifloxacin, protionamide, clofazimine and pyrazi-
namide
Outcomes Risk and treatment outcomes of XDR-TB-Plus
Notes 10 received linezolid, but outcomes were not reported in enough detail to include the study. When contacted for
further data, there was no response from the study authors
Ramirez-Lapausa 2016
Methods Retrospective cohort study
Participants 55 people aged > 17 years, with MDR- or XDR-TB, admitted to hospital
Interventions Individualized ATT regimen of 4-6 drugs
Outcomes Treatment outcomes; AEs
Notes Comparative data were not reported for those receiving versus those not receiving linezolid. When contacted for
further data, there was no response from the study authors
Soman 2014
Methods Retrospective cohort study
Participants 52 consecutive patients with tuberculosis with drug resistance between MDR and XDR: ”We defined MDR+ as
resistance to rifampin (RMP), isoniazid (INH) and at least one more drug other than fluoroquinolone (FQ) and
second-line injectable agent (IA); and Pre-XDR as MDR with additional resistance to either FQ or IA.“
Interventions ”Treatment regimen was devised as per DST [drug susceptibility testing] and predominantly consisted of a second-
line injectable agent (IA), para-aminosalicylic acid (PAS) and clofazimine. Additionally, cycloserine, linezolid, co-
amoxiclav and clarithromycin were used to complete a regimen of four to five drugs.“
Outcomes Clinical and radiological improvement; AEs
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Notes 14 participants received linezolid, but outcomes were not stratified by receipt of linezolid within the publication.
When contacted for further data, there was no response from the study authors
Tornheim 2017
Methods Prospective cohort study
Participants 286 people with MDR-TB
Interventions Not reported in detail in available publication
Outcomes Treatment outcomes, sputum culture conversion, adverse events
Notes 147 participants received linezolid, but outcomes were not reported comparatively for those who did and did not
receive linezolid. The study authors, when contacted, were unable to provide sufficient data to enable classification
Udwadia 2014
Methods Prospective cohort study
Participants 78 ”consecutive patients having a microbiological diagnosis of MDR-TB“; 7% had XDR-TB; 50% had fluoro-
quinolone resistance. ”Surgical resection of the infected lobe or lung was carried out in eight (10.2%) patients.“
Interventions Individualized ATT: ”empirical drug regimen containing at least four drugs they had not previously received while
awaiting their sensitivity report.“
Outcomes Treatment outcomes; AEs
Notes 18 participants received linezolid, but outcomes were not stratified by receipt of linezolid within the publication.
The study authors, when contacted, were unable to provide sufficient data to enable classification
Abbreviations: ATT: antituberculous treatment; AE: adverse event; MDR: multi-drug resistant; TB: tuberculosis; XDR: extensively
drug resistant
Characteristics of ongoing studies [ordered by study ID]
NCT02333799
Trial name or title A phase 3 study assessing the safety and efficacy of bedaquiline plus pa-824 plus linezolid in subjects with
drug resistant pulmonary tuberculosis
Methods Intervention model: single group assignment
Masking: none (open-label)
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Participants Estimated recruitment: 200
Aged ≥ 14 years
Culture-positive pulmonary tuberculosis: MDR-TB with failure of or intolerance to standard second-line
treatment; or XDR-TB
Includes HIV-infected individuals with CD4 cell count > 50 cells/microlitre
Interventions Experimental arm (no control arm): bedaquiline + PA-824 (pretomanid) + linezolid
Outcomes ”Incidence of bacteriologic failure or relapse or clinical failure through follow-up until 24 months after the
end of treatment.“
Starting date March 2015
Contact information Joanna Moreira; Joanna.Moreira@tballiance.org
Dan Everitt; Dan.Everitt@tballiance.org
Notes Estimated completion: October 2021
Countries: South Africa
Linezolid daily dose: 1200 mg
NCT02454205
Trial name or title An open-label RCT to evaluate a new treatment regimen for patients with multi-drug resistant tuberculosis
(NEXT)
Methods Allocation: randomized
Intervention model: parallel assignment
Masking: none (open-label)
Participants Estimated recruitment: 300
Aged ≥ 18 years
”Newly-diagnosed culture and/or GeneXpert positive pulmonary TB“, with rifampicin resistance
Excluded if known to have fluoroquinolone, injectable, XDR or if on MDR-TB treatment for > 2 weeks; or
if known to have rifampicin monoresistance
Includes HIV-infected individuals
Interventions Experimental arm: 6-9 months of oral linezolid; bedaquiline; levofloxacin; pyrazinamide; ethionamide or
high-dose isoniazid or terizidone
Control arm: 21-24 months total therapy; 6-8 month intensive phase of kanamycin; moxifloxacin; pyraz-
inamide; ethionamide and terizidone; continuation phase of moxifloxacin; pyrazinamide; ethionamide and
terizidone
Outcomes Primary outcome: treatment success 24 months after initiation of treatment
Secondary outcomes
• ”Favourable outcome rate
• Time specific rate of treatment failure
• Time specific culture conversion proportions and rates
• Time specific relapse rate
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• Rate of re-infection
• All-cause mortality
• Composite measure of QT interval on ECG, grade 3 and 4 adverse events, stopping drugs (safety and
tolerability end-points)
• Default rate
• Rate of loss of follow-up“
Starting date October 2015
Contact information Aliasgar Esmail; a.esmail@uct.ac.za
Melissa Pascoe; mellissa.pascoe@uct.ac.za
Notes Estimated completion: January 2019
Countries: South Africa
Linezolid daily dose: 600 mg (reduced to 300 mg if toxicity occurs)
NCT02589782
Trial name or title Pragmatic clinical trial for a more effective concise and less toxic MDR-TB treatment regimen(s) (TB-
PRACTECAL)
Methods Allocation: randomized
Intervention model: parallel assignment
Masking: none (open-label)
Participants Estimated recruitment: 630
Aged ≥ 18 years
Culture-confirmed tuberculosis with resistance to at least rifampicin; includes extrapulmonary tuberculosis,
except meningoencephalitis, brain abscesses, osteomyelitis or arthritis
Excluded if known resistance to or prior use of bedaquiline or pretomanid; or prior use of linezolid
Includes HIV-infected individuals
Interventions Experimental regimen 1: 24 weeks of bedaquiline, pretomanid, moxifloxacin and linezolid
Experimental regimen 2: 24 weeks of bedaquiline, pretomanid, linezolid, and clofazimine
Experimental regimen 3: 24 weeks of bedaquiline, pretomanid, and linezolid
Control regimen: ”Locally accepted standard of care which is consistent with the WHO recommendations
for the treatment of M/XDR-TB.“
Outcomes Primary
• Culture conversion at 8 weeks post-randomization
• Treatment discontinuation or death at 8 weeks post-randomization,
• Unfavourable outcome (failure, death, recurrence, loss to follow-up) at 72 weeks post-randomization.
Secondary outcomes
• ≥ grade 3 QT prolongation within 8 weeks post-randomization
• Experiencing ≥ 1 serious or new ≥ grade 3 AE at 8, 72, and 108 weeks post-randomization
• Culture conversion at 12 weeks post-randomization
• Unfavourable outcome (i.e. failure, treatment discontinuation, death, loss to follow-up) at 24 and 108
weeks post-randomization, and at end of treatment
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NCT02589782 (Continued)
• Time to culture conversion
• Change in corrected QT at 24 weeks post-randomization
• Recurrence at week 48 post-randomization
Starting date January 2017
Contact information Kristen LeBeau; kristen.lebeau@london.msf.org
Notes Estimated completion: June 2020
Countries: Belarus, South Africa, Uzbekistan
Linezolid daily dose: ”600mg for 16 weeks then 300mg (or 600mg x3/week) for the remaining 8 weeks or
earlier when moderately tolerated.“
NCT02619994
Trial name or title Treatment shortening of MDR-TB using existing and new drugs (MDR-END)
Methods Allocation: randomized
Intervention model: parallel assignment
Masking: none (open-label)
Participants Estimated recruitment: 238
Aged 19 to 85 years
Known rifampicin-resistant tuberculosis within 14 days of starting tuberculosis therapy; excludes people with
fluoroquinolone-resistant MDR-TB and XDR-TB
No information on testing for of recruitment of people with HIV infection
Interventions Experimental arm: ”Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and
pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.“
Control arm: ”locally-used WHO-approved MDR-TB regimen in Korea“; at least 20 months; ”Intensive
phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.
“
Outcomes Primary outcome: treatment success rate 24 months after treatment start
Secondary outcomes
• Time to sputum culture conversion to negative
• Sputum culture conversion proportion at 2 months of treatment
• Sputum culture conversion proportion at 6 months of treatment
• Number of participants with treatment-related AEs
Starting date January 2016
Contact information Jae-Joon Yim; yimjj@snu.ac.kr
Notes Estimated completion: December 2019
Countries: Republic of Korea
Linezolid daily dose: 600 mg for 2 months, then 300 mg until the end of treatment
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NCT02754765
Trial name or title Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB)
Methods Allocation: randomized
Intervention model: parallel assignment
Masking: none (open-label)
Participants Estimated recruitment: 750
Inclusion criteria
• ≥ 15 years
• Pulmonary tuberculosis with documented resistance to rifampicin and susceptibility to
fluoroquinolones, determined by rapid molecular test.
• Willing to use contraception, if pre-menopausal woman who has not had sterilization procedure.
• “Lives in a dwelling that can be located by study staff and expects to remain in the area for the duration
of the study.”
Exclusion criteria
• Known allergies or hypersensitivity to any of the investigational drugs
• Pregnant or unwilling/unable to stop breast-feeding an infant
• Unable to comply with treatment or follow-up schedule
• Any social or medical condition which, in the opinion of the site principal investigator, would make
study participant unsafe
• Has had exposure in the past 5 years, or resistance to, bedaquiline, delamanid, linezolid, or
clofazimine; exposure to other anti-tuberculosis drugs is not a reason for exclusion
• Has one or more of the following:
• Abnormal blood test results as defined by the study investigators.
• Has cardiac risk factors as defined by the study investigators.
• Is currently taking part in another study of a medicinal product
• Is taking any medication that is contraindicated with the medicines in the study regimen which cannot
be stopped (with or without replacement) or requires a wash-out period > 2 weeks
HIV status: not reported
Interventions 6 arms:
1. Intervention regimen 1: bedaquiline, moxifloxacin, linezolid and pyrazinamide
2. Intervention regimen 2: bedaquiline, clofazimine, levofloxacin, linezolid and pyrazinamide
3. Intervention regimen 3: bedaquiline, delamanid, levofloxacin, linezolid and pyrazinamide
4. Intervention regimen 4: delamanid, clofazimine, levofloxacin, linezolid and pyrazinamide
5. Intervention regimen 5: delamanid, clofazimine, moxifloxacin and pyrazinamide
6. Control regimen: standard of care according to local and WHO guidelines
Outcomes Primary outcome
• Efficacy at week 73 from randomization.
• “Favorable” outcome defined as having negative cultures between week 65 and 73, or lack of positive
cultures with most recent cultures negative and “bacteriological, radiological and clinical evolution is
favorable.”
Secondary outcomes
• Efficacy at week 104 (as for week 73)
• Early (8-week) treatment response, i.e. culture conversion
• Efficacy at week 39 (as for week 73)
• Survival at week 73
• Survival at week 104
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NCT02754765 (Continued)
• Safety at week 73 (proportion of participants with ≥ grade 3 AEs and SAEs)
• Safety at week 104 (as for week 73)
• QTc interval prolongation of ≥ 60 ms from baseline or QTc interval of > 500 ms at week 73
Starting date December 2016
Contact information Celine Delifer; endtb.clinicaltrial@paris.msf.org
Notes Estimated completion: April 2021
Countries: Georgia, Kazakhstan, Kyrgyzstan, Lesotho, Peru, South Africa
Linezolid daily dose: “600 mg QD [per day] for 4 months (followed by 300 mg QD or intermittent dose for
5 months)”
NCT03237182
Trial name or title The individualized M(X) drug-resistant TB treatment strategy study (InDEX)
Methods Allocation: randomized
Intervention model: “Patients randomized to the intervention receive a individualized tuberculosis treatment
based on whole genome sequencing and the patients randomized to the control receive the standard of care
tuberculosis treatment”
Masking: none (open-label)
Participants Estimated recruitment: 300
≥ 18 years
Microbiological (molecular) confirmation of rifampicin-resistant, MDR- or XDR- pulmonary tuberculosis
Includes HIV-infected individuals
Excludes:
• “Persons suffering from any serious acute condition.”
• “Any other chronic or clinically significant medical condition that in the opinion of the attending
clinician would render the patient unsuitable for participation in the study.”
Interventions “Patients with drug resistance will have whole genome sequencing performed on the respective positiveMGIT
sample. An individualized TB treatment regimen will be provided to patients based on the whole genome
sequencing results.”
Individuals in the control arm will have South African standard drug-resistant tuberculosis treatment regimen
Outcomes Primary outcome
Time to culture conversion from positive to negative; on 2 consecutive samples 30 days apart for MDR-TB
and 3 consecutive samples 30 days apart each for people with XDR-TB
Secondary outcomes
• Tuberculosis treatment outcomes: treatment success, mortality, retention in care
• AEs compared between each arm
• Characterization of the strains: “The minimum inhibitory concentrations of Mtb isolates will be
correlated with the genotypic mutations detected and the evolution of drug resistance will be monitored by
comparing serial isolates from patients”
Starting date June 2017
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NCT03237182 (Continued)
Contact information Natasha Gounden; natasha.gounden@caprisa.org
Resha Boodhram; resha.boodhram@caprisa.org
Notes Estimated completion: December 2021
Countries: South Africa
Linezolid daily dose: not reported
Other: linezolid is listed as a possible drug in both arms, but it is likely in the review authors’ opinion that
some will receive and others will not receive linezolid
Abbreviations: ATT: antituberculous treatment; AE: adverse event; ECT: electrocardiogram; MDR: multi-drug resistant; SAE: serious
adverse event; TB: tuberculosis; WHO: World Health Organization; XDR: extensively drug resistant
A D D I T I O N A L T A B L E S
Table 1. Summary of characteristics of included studies
Study Study
design
Coun-
try
Recruit-
ment
dates
Age Drug
resis-
tance
HIV
status
re-
ported
Line-
zolid
daily
dose
Line-
zolid
dura-
tion
Number of participants
Line-
zolid
No line-
zolid
Total
Lee
2012
RCT, no
placebo,
partial
blinding
Re-
public of
Korea
2008 to
2011
Adults >
20 years
All XDR Yes, ex-
cluded
600
mg, then
random-
ized to
300 mg
or 600
mg
Median
781 days
19 im-
mediate
20
delayed
39
Paday-
atchi
2012
RCT,
placebo,
blinding
South
Africa
2009 to
2010
Adults >
18 years
All
MDR
Yes, in-
cluded,
mostly
on an-
tiretrovi-
rals
600 mg 112 days 16 18 34
Tang
2015
RCT, no
placebo/
blinding
China 2009 to
2011
Adults
18 to 64
years
All XDR Yes, ex-
cluded
1200 mg
4 to
6 weeks,
then 300
to 600
mg
Un-
til spu-
tum cul-
ture neg-
ative
33 32 65
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Table 1. Summary of characteristics of included studies (Continued)
Migliori
2009
Retro-
spective
cohort
Belarus,
Ger-
many,
Italy,
Switzer-
land
2001 to
2007
Not re-
ported
18/195
XDR,
rest
MDR
No 600 to
1200 mg
Median
93 days
85 110 195
Udwa-
dia
2010
Prospec-
tive co-
hort
India 2000 to
2007
Adults >
18 years
7/18
XDR,
rest
MDR
(line-
zolid
group)
No 1200 mg Mean
247 days
18 60 78
Jo 2014 Retro-
spective
cohort
Re-
public of
Korea
2006 to
2012
Adults
>18
years
26/70
XDR,
rest
MDR;
all
ofloxacin-
resistant
Yes, 9/
70 tested
- all neg-
ative
300 to
600 mg
Median
259 days
26 44 70
Seddon
2014
Retro-
spective
cohort
South
Africa
2009 to
2012
Chil-
dren <
15 years
6/149
(2/3 re-
ceiving
line-
zolid)
XDR,
16/
149 ri-
fampicin-
monore-
sistant,
rest
MDR
Yes, in-
cluded,
mostly
on an-
tiretrovi-
rals
Un-
known
Median
480 days
3 146 149
Zhang
2014
Retro-
spective
cohort
China 2012 to
2013
Adults >
18 years
All XDR Yes, all
negative
600 mg Un-
known
(”at least
one
month“)
15 28 43
Jeong
2015
Retro-
spective
cohort
Re-
public of
Korea
2005 to
2011
Adults >
18 years
All
fluoro-
quinolone-
resistant
MDR,
or XDR
Yes,
no HIV-
pos-
itive par-
ticipants
300 to
600 mg
Median
426 days
58 86 144
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Table 1. Summary of characteristics of included studies (Continued)
Kwak
2015
Retro-
spective
cohort
Re-
public of
Korea
2006 to
2010
Not re-
ported
26/123
XDR,
rest
MDR
No Un-
known
Un-
known
12 111 123
Van
Altena
2015
Retro-
spective
cohort
Nether-
lands
2000 to
2009
Not re-
ported
4/112
XDR,
rest
MDR
Yes, in-
cluded
600 mg Mean 99
days,
median
56 days
53 51 104
Galli
2016
Retro-
spective
cohort
Italy 2010 to
2012
Chil-
dren <
18 years
1/11
XDR,
rest
MDR
No Un-
known
Un-
known
5 6 11
Jense-
nius
2016
Retro-
spective
cohort
Norway 1995 to
2014
All,
range
2 to 57
years
6/89
XDR,
rest
MDR
Yes, in-
cluded
”Usu-
ally“
1200 mg
Un-
known
52 16 68
Tiberi
2016
Retro-
spective
cohort
Belarus,
Bel-
gium,
Brazil,
Ecuador,
Greece,
Hol-
land,
Italy,
Peru,
Slo-
vakia,
UK
2003 to
2015
Adults >
15 years
XDR
and
MDR
Yes, in-
cluded,
mostly
on an-
tiretrovi-
rals
300 to
1200 mg
Un-
known
267 81 348
Gugliel-
metti
2017
Retro-
spective
cohort
France 2011 to
2013
Not re-
ported
24/45
XDR
Yes, in-
cluded
600 mg Un-
known
43 2 45
Ferlazzo
2018
Retro-
spective
cohort
Arme-
nia, In-
dia,
South
Africa
2016 >
18 years
and one
14-year
old
14/28
XDR,
rest
MDR
(10
fluoro-
quinolone
resis-
tant)
Yes, in-
cluded
Un-
known
Un-
known
23 5 28
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Table 1. Summary of characteristics of included studies (Continued)
Olayanju
2018
Prospec-
tive co-
hort
South
Africa
2008 to
2017
Adults >
18 years
All XDR Yes, in-
cluded
Un-
known
Un-
known
55 217 272
Abbreviations: MDR: multi-drug resistant; RCT: randomized controlled trial; XDR: extensively drug resistant.
Table 2. Findings from the Lee 2012 randomized trial
Factor Participants who received
linezolid immediately
Participants who received de-
layed linezolid
Relative effect RR (95% CI)
Study characteristics Korea, all XDR, HIV co-infection excluded, adults -
Participants 19 20 -
Death 0/19 0/20 Unable to calculate
Sputum culture conversion at 4
months
15/19 (78.9%) 7/20 (35.0%) 2.26 (1.19 to 4.28)
Total adverse events 56a N/A
Serious adverse events 37a N/A
Linezolid discontinuation 7/39 (17.9%) N/A
aAdverse events reported without disaggregation for linezolid receipt being immediate or delayed; total adverse events reported in Lee
2012 but not updated in 2015 article; serious adverse events updated in 2015 article (in 2012 article, 33 were reported)
Abbreviations: CI: confidence interval; N/A: not applicable; RR: risk ratio; XDR: extensively drug-resistant
Table 3. Findings from the Tang 2015 randomized trial
Factor Participants who received
linezolid
Participants who did not re-
ceive linezolid
Relative effect RR (95% CI)
Study characteristics China, all XDR, HIV co-infection excluded, adults
Participants 33 32 -
Death 2/33 (6.1%) 3/32 (9.4%) 0.65 (0.12 to 3.62)
Failure 4/33 (12.1%) 15/32 (46.9%) 0.26 (0.10 to 0.70)
Cure 17/33 (51.5%) 7/32 (21.9%) 2.36 (1.13 to 4.90)
Treatment completed 6/33 (18.2%) 4/32 (12.5%) 1.45 (0.45 to 4.68)
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Table 3. Findings from the Tang 2015 randomized trial (Continued)
Treatment interruption (”de-
fault“)
4/33 (12.1%) 3/32 (9.4%) 1.29 (0.31 to 5.33)
Sputum culture conversion at
24 months
26/33 (78.8%) 12/32 (37.6%) 2.10 (1.30 to 3.40)
Total adverse events 74 28 Unable to calculate
Serious adverse events NR NR Unable to calculate
Linezolid discontinuation 2/33 (6.1%) N/A N/A
Abbreviations: CI: confidence interval; N/A: not applicable; NR: not reported; RR: risk ratio; XDR: extensively drug-resistant
Table 4. Sensitivity analysis for Tang 2015
Sensitivity analysis Participants who received
linezolid
Participants who did not re-
ceive linezolid
Relative effect RR (95% CI)
Death
ITT analysis (as in review pro-
tocol)
2/33 3/32 0.65 (0.12 to 3.62)
Worst-case analysis 6/33 3/32 1.94 (0.53 to 7.10)
Best-case analysis 2/33 6/32 0.32 (0.07 to 1.48)
Cure
ITT analysis (as in review pro-
tocol)
17/33 7/32 2.36 (1.13 to 4.90)
Worst-case analysis 17/33 10/32 1.65 (0.89 to 3.04)
Best-case analysis 21/33 7/32 2.91 (1.44 to 5.88)
Failure
ITT analysis (as in review pro-
tocol)
4/33 15/32 0.26 (0.10 to 0.70)
Worst-case analysis 8/33 15/32 0.52 (0.26 to 1.05)
Best-case analysis 4/33 18/32 0.22 (0.08 to 0.57)
Abbreviations: CI: confidence interval; ITT: intention to treat; RR: risk ratio.
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Table 5. Summary of findings in non-randomized studies
Baseline characteristics Participants who received linezolid Participants who did not receive linezolid
Number of studies re-
porting outcomes
12 6
Participants 639 participants, including 8 children 487 participants, including 160 children
Proportion with XDR-
TBa
440/1137 (38.7%) 343/628 (54.6%)
Included participants
with HIV
8/12 4/6
Outcomes Number of events Number of participants
(studies)
Number of events Number of participants
(studies)
Total adverse events 602 426 (8) 813 478 (5)
Serious adverse events 57 164 (7) 47 270 (5)
Linezolid
discontinuation
141 624 (11) N/A N/A
aWhere reported; not disaggregated for participants receiving linezolid
Abbreviation: XDR: extensively drug-resistant
Table 6. Adverse events outcomes data in non-randomized studies
Study Total adverse events Serious adverse events Linezolid
discontin-
uation
Linezolid-attributed adverse events Our ob-
servations
Linezolid No
linezolid
Linezolid No
linezolid
Total Neuropa-
thy
Bone mar-
row
Migliori
2009
NR NR NR NR 19/85 52/85 3/85 30/85 No com-
parative
data
Udwadia
2010
NR NR NR NR NR 9/18 8/18 1/18 No com-
parative
data
Jo 2014 20/26 NR 6/26 NR 8/26 22/26 16/26 2/26 No com-
parative
data
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Table 6. Adverse events outcomes data in non-randomized studies (Continued)
Seddon
2014
0/3 245/142 0/3 11/146 0/3 0/3 0/3 0/3 No RR/
P-value re-
ported;
small
group re-
ceived line-
zolid
Zhang
2014
11/15 NR NR NR NR 11/15 1/15 4/15 No com-
parative
data
Kwak
2015
8/12 36/111 8/12 32/111 2/12 3/12 2/12 0/12 No RR/
P-value re-
ported;
linezolid
added if
failing
therapy, or
XDR
Jeong
2015
- - - - - - - - Jeong
2015 re-
ported no
ad-
verse event
data other
than line-
zolid dose
reduction
Van Altena
2015
NR NR NR NR 5/53 NR NR NR No com-
parative
data
Galli 2016 2/5 0/6 0/5 0/6 0/5 2/5 0/5 1/5 No RR/
P-value re-
ported;
small sam-
ple size
Jensenius
2016
NR NR 23/52 NR 23/52 NR NR NR No com-
parative
data
Tiberi
2016
253/267 NR NR NR 61/267 97/267 47/267 50/267 No com-
parative
data
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Table 6. Adverse events outcomes data in non-randomized studies (Continued)
Gugliel-
metti
2017
127/43 7/2 8/43 0/2 5/43 31/43 22/43 9/43 No RR/
P-value re-
ported;
small con-
trol group;
post-hoc
analysis
Ferlazzo
2018
NR NR 12/23 4/5 0/23 NR NR NR No RR/
P-value re-
ported;
post-hoc
analysis
Olayanju
2018
181/55 525/217 NR NR 18/55 NR 12/55 11/55 No RR/
P-value re-
ported;
post-hoc
analysis
Abbreviations: NR: not reported; RR: risk ratio; XDR: extensively drug-resistant.
Table 7. Previous systematic reviews of linezolid for drug-resistant tuberculosis
Study Unit of
analysis
Risk of
bias as-
sessment
Type and
num-
ber of in-
cluded
studies
Number
of partic-
ipants
who
received
linezolid
Number
of partic-
ipants
who did
not
receive
linezolid
Studies
in coun-
tries with
high tu-
berculo-
sisbur-
dena
Effi-
cacy out-
comes as-
sessed
Adverse
events
out-
comes as-
sessed
Main re-
sults
Authors’
conclu-
sions
Cox 2012 Study Not per-
formed
11 case
series
148 0 1/11 Yes Yes Treat-
ment suc-
cess: 68%
Adverse
events in-
cidence:
61%
Line-
zolid dis-
continua-
tion:
36%
“…Line-
zolid ap-
pears…a
useful
drug…with
signif-
icant
adverse
events,
and
should
be con-
sidered
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Table 7. Previous systematic reviews of linezolid for drug-resistant tuberculosis (Continued)
in the
treatment
of com-
plicated
DR-TB.”
Sotgiu
2012
Study Not per-
formed
12 non-
random-
ized stud-
ies
121 0 2/12 Yes Yes Treat-
ment suc-
cess:
82%.
Adverse
events in-
cidence:
59%
“… excel-
lent effi-
cacy but
also
the neces-
sity of
caution
in the
prescrip-
tion of
linezolid.
”
Chang
2013c
Individ-
ual par-
ticipant
data
Not per-
formed
20 non-
random-
ized stud-
ies
162 32 3/
12 (coun-
tries)
Yes No RR for
favourable
outcome
with
linezolid
use vs
without:
1.55
(95% CI
1.10 to 2.
21)
“Our
findings
substanti-
ated the
use of
linezolid
in the
treatment
of XDR-
TB or
fluoro-
quinolone-
resistant
MDR-
TB”
Zhang
2015
Study Not per-
formed
One
RCT and
14 non-
random-
ized stud-
ies
367 0 3/15 Yes Yes Treat-
ment suc-
cess: 83%
(95% CI
75 to 90)
Pooled
mortality
lower (P
< 0.001)
and ner-
vous sys-
tem
adverse
“…Line-
zolid
could be
con-
sidered as
a promis-
ing
option as
treatment
of MDR/
XDR TB.
”
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Table 7. Previous systematic reviews of linezolid for drug-resistant tuberculosis (Continued)
events
higher (P
< 0.01) if
receiv-
ing < 600
mg/day
Ahmad
2018
Individ-
ual par-
ticipant
data
Yes 50 non-
random-
ized co-
hort stud-
ies and
case series
1011 11019 22/50
(recruit-
ing from
≥1 high-
burden
country)
Yes No For treat-
ment suc-
cess with
linezolid
use vs
without:
crude OR
1.5 (95%
CI 1.2 to
1.9)
, adjusted
OR 3.4
(2.6 to 4.
5)
, adjusted
RD 0.15
(0.11 to
0.18)
For death
with line-
zolid use
vs
without:
crude OR
0.4 (95%
CI 0.3 to
0.5)
, adjusted
OR
0.3 (95%
CI 0.2 to
0.3)
, adjusted
RD −0.
20 (95%
CI −0.23
to−0.16)
“Al-
though
infer-
ences are
limited
by the ob-
serva-
tional na-
ture of
these
data,
treatment
outcomes
were
signif-
icantly
better
with use
of line-
zolid…for
treatment
of mul-
tidrug-
resistant
tubercu-
losis.”
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Table 7. Previous systematic reviews of linezolid for drug-resistant tuberculosis (Continued)
For peo-
ple with
XDR-
TB,
adjusted
ORs (suc-
cess 6.6
(95% CI
4.1 to 10.
6), death
0.2 (95%
CI 0.1 to
0.3)) and
RDs (suc-
cess 0.31
(95% CI
0.24 to 0.
38),
death−0.
29 (95%
CI −0.36
to−0.23)
)
remained
signif-
icantly in
favour of
linezolid
use
Abbreviations: CI: confidence interval; DR: drug resistant; MDR: multi-drug resistant; N/A: not applicable; OR: odds ratio; RD: risk
difference; RR: risk ratio; XDR: extensively drug-resistant.
aHigh-tuberculosis-burden countries as defined in WHO 2015b.
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A P P E N D I C E S
Appendix 1. Search strategy
Search set CIDG SR CENTRAL MEDLINE Embase LILACS
1 Tuberculosis OR TB Tuberculosis OR TB
ti, ab
Tuberculosis OR TB
ti, ab
Tuberculosis OR TB
ti, ab
Tuberculosis OR TB
2 Multi-drug resistant drug resist* ORMDR
OR DR OR XDR ti,
ab
drug resist* ORMDR
OR DR OR XDR ti,
ab
drug resist* ORMDR
OR DR OR XDR ti,
ab
Multi-drug resistant
3 MDR-TB 1 and 2 1 and 2 1 and 2 MDR-TB
4 Drug-resistant DR-TB OR MDR-
TB OR XDR-TB ti,
ab
DR-TB OR MDR-
TB OR XDR-TB ti,
ab
DR-TB OR MDR-
TB OR XDR-TB ti,
ab
Drug-resistant
5 XDR-TB Tuberculo-
sis, Multidrug-Resis-
tant”[Mesh] OR “Ex-
tensively Drug-Resis-
tant
Tuberculosis”[Mesh]
Tuberculo-
sis, Multidrug-Resis-
tant“[Mesh] OR ”Ex-
tensively Drug-Resis-
tant
Tuberculosis“[Mesh]
Multidrug resistant
tuberculosis [Emtree]
OR “extensively drug
resistant tuberculosis”
[Emtree] OR “drug
resistant tuberculosis”
[Emtree]
XDR-TB
6 2 or 3 or 4 or 5 3 or 4 or 5 3 or 4 or 5 3 or 4 or 5 2 or 3 or 4 or 5
7 1 and 6 ”Oxazolidi-
nones“[Mesh]
”Oxazolidi-
nones“[Mesh]
Linezolid ti, ab OR
“Linezolid” [Emtree]
1 and 6
8 linezolid ”linezolid“ [Supple-
mentary Concept]
”linezolid“ [Supple-
mentary Concept]
LZD OR Zyvox ti, ab linezolid
9 7 and 8 Linezolid OR LZD
OR Zyvox ti, ab
Linezolid OR LZD
OR Zyvox ti, ab
“oxazolidinone
derivative” [Emtree]
7 and 8
10 - 7 or 8 or 9 7 or 8 or 9 7 or 8 or 9 -
11 - 6 and 10 6 and 10 6 and 10 -
12 - - Limit 11 to Humans Limit 11 to Human -
82Linezolid for drug-resistant pulmonary tuberculosis (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
C O N T R I B U T I O N S O F A U T H O R S
BS and DC assessed the eligibility of the studies and extracted the data. BS, DC and HR assessed risk of bias of the included studies.
BS drafted the text. DC, HR and DS gave input to the final draft. All review authors read and approved the final version of the review.
BS is the guarantor of the review.
D E C L A R A T I O N S O F I N T E R E S T
BS is a Clinical Research Fellow for the NIHR Global Health Research Group on Brain Infections at the University of Liverpool, and
also works at the Royal Liverpool University Hospital, UK, and has no known conflicts of interest.
HR works at the Royal Liverpool University Hospital, UK, and has no known conflicts of interest.
DC is a PhDcandidate supported by aWellcomeTrust Clinical Training Fellowship, based at the Liverpool School of TropicalMedicine,
UK, and has no known conflicts of interest.
DS is a Senior Clinical Lecturer at the University of St Andrews, UK, and is a principal or co-investigator on projects funded through
grants from the Cunningham Trust, the Wellcome Trust, MRC-Newton Fund, and EDCTP, and has no known conflicts of interest.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
Project number 300342-104
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Following peer review, we amended the Dealing with missing data and Assessment of reporting biases sections. We clarified that we
would assume missing participants to have not experienced the outcome being assessed, and aminimum of 10 studies would be required
for construction of a funnel plot, respectively.
Editorial review prompted consideration of performing a sensitivity analysis on the third primary outcome, failure. We included this,
which is reflected in amendments within the relevant tables (Table 4 and Summary of findings for the main comparison), and sections
of the text (Dealing with missing data, Sensitivity analysis, Effects of interventions, and Summary of main results).
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